Kleinert, Stefan: [Cardiovascular risk in inflammatory rheumatic diseases : Evidence-based strategies for risk reduction in rheumatologic practice]. In: Z Rheumatol, 2026, ISSN: 1435-1250. @article{pmid41949759,
title = {[Cardiovascular risk in inflammatory rheumatic diseases : Evidence-based strategies for risk reduction in rheumatologic practice]},
author = {Stefan Kleinert},
doi = {10.1007/s00393-026-01800-w},
issn = {1435-1250},
year = {2026},
date = {2026-04-01},
journal = {Z Rheumatol},
abstract = {Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) have a persistently increased cardiovascular (CV) risk and higher mortality, independently of traditional CV risk factors. Effective control of inflammation reduces CV events, whereas glucocorticoids increase the risk in a dose- and duration-dependent manner, even at ≤ 5 mg prednisolone/day. Disease-modifying antirheumatic drugs especially tumor necrosis factor (TNF) inhibitors, are largely protective through the reduction of systemic inflammation. For patients receiving Janus kinase (JAK) inhibitors or long-term glucocorticoid therapy, a structured CV risk assessment and guideline-based management of modifiable risk factors (including lipid optimization/statin therapy) are essential. Primary prevention should be based on the cardiovascular prevention guidelines of the European Society of Cardiology (ESC). Vaccinations (influenza, COVID-19, pneumococcus, respiratory syncytial virus, zoster) represent an effective pillar of CV prevention in populations at cardiovascular risk; however, evidence in patients with inflammatory rheumatic diseases is still lacking. The main challenge for CV prevention remains implementation: digital clinical reminders/decision support systems and multicomponent strategies can improve the implementation of recommendations.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) have a persistently increased cardiovascular (CV) risk and higher mortality, independently of traditional CV risk factors. Effective control of inflammation reduces CV events, whereas glucocorticoids increase the risk in a dose- and duration-dependent manner, even at ≤ 5 mg prednisolone/day. Disease-modifying antirheumatic drugs especially tumor necrosis factor (TNF) inhibitors, are largely protective through the reduction of systemic inflammation. For patients receiving Janus kinase (JAK) inhibitors or long-term glucocorticoid therapy, a structured CV risk assessment and guideline-based management of modifiable risk factors (including lipid optimization/statin therapy) are essential. Primary prevention should be based on the cardiovascular prevention guidelines of the European Society of Cardiology (ESC). Vaccinations (influenza, COVID-19, pneumococcus, respiratory syncytial virus, zoster) represent an effective pillar of CV prevention in populations at cardiovascular risk; however, evidence in patients with inflammatory rheumatic diseases is still lacking. The main challenge for CV prevention remains implementation: digital clinical reminders/decision support systems and multicomponent strategies can improve the implementation of recommendations. |
Strunz, Patrick-Pascal; Risser, Linus Maximilian; Englbrecht, Matthias; Witte, Torsten; Fröhlich, Matthias; Schmalzing, Marc; Gernert, Michael; Heck, Johannes; Bartz-Bazzanella, Peter; von der Decken, Cay; Karberg, Kirsten; Gauler, Georg; Späthling-Mestekemper, Susanna; Kuhn, Christoph; Vorbrüggen, Wolfgang; Welcker, Martin; Kleinert, Stefan: [Renewed increase in new Janus kinase inhibitor prescriptions : Analysis of the German RHADAR registry]. In: Z Rheumatol, Bd. 85, Nr. 1, S. 73–79, 2026, ISSN: 1435-1250. @article{pmid40986019,
title = {[Renewed increase in new Janus kinase inhibitor prescriptions : Analysis of the German RHADAR registry]},
author = {Patrick-Pascal Strunz and Linus Maximilian Risser and Matthias Englbrecht and Torsten Witte and Matthias Fröhlich and Marc Schmalzing and Michael Gernert and Johannes Heck and Peter Bartz-Bazzanella and Cay von der Decken and Kirsten Karberg and Georg Gauler and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Stefan Kleinert},
doi = {10.1007/s00393-025-01728-7},
issn = {1435-1250},
year = {2026},
date = {2026-02-01},
journal = {Z Rheumatol},
volume = {85},
number = {1},
pages = {73--79},
abstract = {BACKGROUND: Regulatory safety recommendations regarding Janus kinase inhibitors (JAKi) led to a marked decline in new prescriptions in Germany. In the meantime, professional medical societies have also issued differentiated recommendations.nnOBJECTIVES: The aim was to investigate the RHADAR (RheumaDatenRhePort) registry to check whether JAKi prescriptions recovered thereafter.nnMATERIALS AND METHODS: A retrospective analysis of new prescriptions for JAKi, tumor necrosis factor inhibitors (TNFi), and interleukin‑6 receptor inhibitors (IL-6Ri) in patients with rheumatoid arthritis between 1 April 2020, and 30 September 2024. The primary endpoint was the proportion of JAKi among all new prescriptions of these three drug classes per half-year. The treatment line of JAKi use was additionally assessed.nnRESULTS: A total of 3492 treatment initiations were recorded in the registry during the observation period (TNFi: n = 1770, 50.7%, JAKi: n = 1269, 36.3%, IL-6Ri: n = 453, 13.0%). The proportion of JAKi initially rose from 29.5% (Q2-Q3/2020) to 46.9% (Q2-Q3/2021), followed by a decline to 24.4% (Q2-Q3/2023) after the regulatory safety communications. Since Q4/2023, a renewed increase has been observed (32.8%), though not yet reaching previous peak levels. JAKi were increasingly shifted from early to advanced treatment lines (≥ 3rd line).nnCONCLUSION: Following the decline in JAKi prescriptions due to European Medicines Agency safety recommendations, a renewed increase has been observed. Since then, JAKi have been predominantly used in later treatment lines, indicating a more differentiated approach to this drug class.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Regulatory safety recommendations regarding Janus kinase inhibitors (JAKi) led to a marked decline in new prescriptions in Germany. In the meantime, professional medical societies have also issued differentiated recommendations.nnOBJECTIVES: The aim was to investigate the RHADAR (RheumaDatenRhePort) registry to check whether JAKi prescriptions recovered thereafter.nnMATERIALS AND METHODS: A retrospective analysis of new prescriptions for JAKi, tumor necrosis factor inhibitors (TNFi), and interleukin‑6 receptor inhibitors (IL-6Ri) in patients with rheumatoid arthritis between 1 April 2020, and 30 September 2024. The primary endpoint was the proportion of JAKi among all new prescriptions of these three drug classes per half-year. The treatment line of JAKi use was additionally assessed.nnRESULTS: A total of 3492 treatment initiations were recorded in the registry during the observation period (TNFi: n = 1770, 50.7%, JAKi: n = 1269, 36.3%, IL-6Ri: n = 453, 13.0%). The proportion of JAKi initially rose from 29.5% (Q2-Q3/2020) to 46.9% (Q2-Q3/2021), followed by a decline to 24.4% (Q2-Q3/2023) after the regulatory safety communications. Since Q4/2023, a renewed increase has been observed (32.8%), though not yet reaching previous peak levels. JAKi were increasingly shifted from early to advanced treatment lines (≥ 3rd line).nnCONCLUSION: Following the decline in JAKi prescriptions due to European Medicines Agency safety recommendations, a renewed increase has been observed. Since then, JAKi have been predominantly used in later treatment lines, indicating a more differentiated approach to this drug class. |
Regierer, Anne C; Karberg, Kirsten; von der Decken, Cay-Benedict; Lembke, Stephanie; Veltri, Carlo; Englbrecht, Matthias; Callhoff, Johanna; Kleinert, Stefan: Discordance between patient and physician reported global disease activity in PsA is associated with mental health-a cross-sectional analysis. In: Rheumatol Int, Bd. 45, Nr. 8, S. 181, 2025, ISSN: 1437-160X. @article{pmid40762812,
title = {Discordance between patient and physician reported global disease activity in PsA is associated with mental health-a cross-sectional analysis},
author = {Anne C Regierer and Kirsten Karberg and Cay-Benedict von der Decken and Stephanie Lembke and Carlo Veltri and Matthias Englbrecht and Johanna Callhoff and Stefan Kleinert},
doi = {10.1007/s00296-025-05933-0},
issn = {1437-160X},
year = {2025},
date = {2025-08-01},
journal = {Rheumatol Int},
volume = {45},
number = {8},
pages = {181},
abstract = {Psoriatic arthritis (PsA) is a complex disease with heterogeneous disease manifestations. Composite scores including patient reported parameters are the recommended tools to measure these different aspects. Patient and physician often show discordance in their disease assessment. To describe the discordance between patient (PtGA) and physician reported global disease activity (PhGA) and to show its association with mental health. Descriptive cross-sectional analysis of three independent cohorts of PsA patients - RABBIT-SpA register, national database (NDB), RheumaDatenRheport GbR (RHADAR) network - receiving routine rheumatology care in Germany. Association between depressive symptoms and discordance between PtGA and PhGA was analysed using a linear regression model taking age, sex, and depression score into account. 1931 RABBIT-SpA, 1794 NDB, and 1728 RHADAR patients were analysed. Mean age was 55, 56, and 60 years. Mean discordance (PtGA-PhGA) was 1.8 in RABBIT-SPA, 1.9 in NDB, and 2 in RHADAR. Discordance > = 3 was present in 34% (RABBIT-SpA), 35% (NDB), and 37% (RHADAR). Discordance increased with increasing PtGA. In patients with severe depressive symptoms, discordance was larger than in those with no depressive symptoms. Depressive symptoms were significantly associated with discordance also if age and sex were accounted for. In this analysis of three independent PsA cohorts, we found a clinically meaningful discordance between physician and patient assessed disease activity in more than a third of the patients. As patients report higher levels of disease activity, discordant judgments become increasingly prevalent. Depressive symptoms are strongly associated with discordant assessments of global disease activity.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Psoriatic arthritis (PsA) is a complex disease with heterogeneous disease manifestations. Composite scores including patient reported parameters are the recommended tools to measure these different aspects. Patient and physician often show discordance in their disease assessment. To describe the discordance between patient (PtGA) and physician reported global disease activity (PhGA) and to show its association with mental health. Descriptive cross-sectional analysis of three independent cohorts of PsA patients - RABBIT-SpA register, national database (NDB), RheumaDatenRheport GbR (RHADAR) network - receiving routine rheumatology care in Germany. Association between depressive symptoms and discordance between PtGA and PhGA was analysed using a linear regression model taking age, sex, and depression score into account. 1931 RABBIT-SpA, 1794 NDB, and 1728 RHADAR patients were analysed. Mean age was 55, 56, and 60 years. Mean discordance (PtGA-PhGA) was 1.8 in RABBIT-SPA, 1.9 in NDB, and 2 in RHADAR. Discordance > = 3 was present in 34% (RABBIT-SpA), 35% (NDB), and 37% (RHADAR). Discordance increased with increasing PtGA. In patients with severe depressive symptoms, discordance was larger than in those with no depressive symptoms. Depressive symptoms were significantly associated with discordance also if age and sex were accounted for. In this analysis of three independent PsA cohorts, we found a clinically meaningful discordance between physician and patient assessed disease activity in more than a third of the patients. As patients report higher levels of disease activity, discordant judgments become increasingly prevalent. Depressive symptoms are strongly associated with discordant assessments of global disease activity. |
Decken, Cay-Benedict; Kleinert, Stefan; Englbrecht, Matthias; Karberg, Kirsten; Gauler, Georg; Ronneberger, Monika; Rapp, Praxedis; Schuch, Florian; Wendler, Joerg; Späthling-Mestekemper, Susanna; Kuhn, Christoph; Vorbrüggen, Wolfgang; Welcker, Martin; Bartz-Bazzanella, Peter: RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings. In: Rheumatol Int, Bd. 45, Nr. 5, S. 129, 2025, ISSN: 1437-160X. @article{pmid40293492,
title = {RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings},
author = {Cay-Benedict Decken and Stefan Kleinert and Matthias Englbrecht and Kirsten Karberg and Georg Gauler and Monika Ronneberger and Praxedis Rapp and Florian Schuch and Joerg Wendler and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Peter Bartz-Bazzanella},
doi = {10.1007/s00296-025-05861-z},
issn = {1437-160X},
year = {2025},
date = {2025-04-01},
journal = {Rheumatol Int},
volume = {45},
number = {5},
pages = {129},
abstract = {More efficient means of identifying patients with inflammatory rheumatic diseases (IRDs) could allow earlier diagnosis and treatment. The objective of this study was to evaluate the characteristics of a revised version of an online patient questionnaire-based self-referral tool, RhePort 1.3. This prospective study included adult patients with musculoskeletal complaints presenting for a first rheumatology visit at German RheumaDatenRhePort (RHADAR) rheumatology network centers. All patients completed the RhePort 1.3 questionnaire on patient characteristics and symptoms. Data from RhePort 1.3 were compared with historical data from previous versions. Of 614 patients, 225 (36.6%) were diagnosed with an IRD by a rheumatologist and 164/225 IRD patients (72.9%) had a RhePort 1.3 score > 1, the cut-off point used to determine the need for rheumatologic evaluation. A score > 1 was associated with an approximately two-fold higher IRD risk (odds ratio [95% confidence interval] of 1.98 [1.39, 2.83] vs ≤ 1) and had good sensitivity (73%) and moderate specificity (42%). Among patients referred through a standard referral pathway (n = 283), RhePort 1.3 scores > 1 in addition to physician referral were associated with increases in rheumatology-diagnosed IRD rates from 33.2% (physician referral only) to 45.7%. RhePort 1.3 had higher accuracy than earlier versions (54% vs 35%). We conclude that modest changes to the RhePort questionnaire resulted in increased accuracy. A score > 1 was associated with a doubled risk for an IRD and higher IRD rates in physician-referred patients. These data suggest that RhePort has the potential to streamline the rheumatologist's workload and improve resource use. Further modifications are required to improve specificity.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
More efficient means of identifying patients with inflammatory rheumatic diseases (IRDs) could allow earlier diagnosis and treatment. The objective of this study was to evaluate the characteristics of a revised version of an online patient questionnaire-based self-referral tool, RhePort 1.3. This prospective study included adult patients with musculoskeletal complaints presenting for a first rheumatology visit at German RheumaDatenRhePort (RHADAR) rheumatology network centers. All patients completed the RhePort 1.3 questionnaire on patient characteristics and symptoms. Data from RhePort 1.3 were compared with historical data from previous versions. Of 614 patients, 225 (36.6%) were diagnosed with an IRD by a rheumatologist and 164/225 IRD patients (72.9%) had a RhePort 1.3 score > 1, the cut-off point used to determine the need for rheumatologic evaluation. A score > 1 was associated with an approximately two-fold higher IRD risk (odds ratio [95% confidence interval] of 1.98 [1.39, 2.83] vs ≤ 1) and had good sensitivity (73%) and moderate specificity (42%). Among patients referred through a standard referral pathway (n = 283), RhePort 1.3 scores > 1 in addition to physician referral were associated with increases in rheumatology-diagnosed IRD rates from 33.2% (physician referral only) to 45.7%. RhePort 1.3 had higher accuracy than earlier versions (54% vs 35%). We conclude that modest changes to the RhePort questionnaire resulted in increased accuracy. A score > 1 was associated with a doubled risk for an IRD and higher IRD rates in physician-referred patients. These data suggest that RhePort has the potential to streamline the rheumatologist's workload and improve resource use. Further modifications are required to improve specificity. |
Risser, Linus Maximilian; Witte, Torsten; Englbrecht, Matthias; Strunz, Patrick-Pascal; Froehlich, Matthias; Schmalzing, Marc; Gernert, Michael; Bartz-Bazzanella, Peter; Decken, Cay; Karberg, Kirsten; Gauler, Georg; Späthling-Mestekemper, Susanna; Kuhn, Christoph; Vorbrüggen, Wolfgang; Welcker, Martin; Kleinert, Stefan: Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database. In: Rheumatol Int, Bd. 45, Nr. 5, S. 100, 2025, ISSN: 1437-160X. @article{pmid40232336,
title = {Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database},
author = {Linus Maximilian Risser and Torsten Witte and Matthias Englbrecht and Patrick-Pascal Strunz and Matthias Froehlich and Marc Schmalzing and Michael Gernert and Peter Bartz-Bazzanella and Cay Decken and Kirsten Karberg and Georg Gauler and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Stefan Kleinert},
doi = {10.1007/s00296-025-05859-7},
issn = {1437-160X},
year = {2025},
date = {2025-04-01},
journal = {Rheumatol Int},
volume = {45},
number = {5},
pages = {100},
abstract = {Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept, interleukin-6 inhibitors (IL-6i) and tumor necrosis factor inhibitors (TNFi). Real-world data regarding treatment persistence and drug survival in the time period following the approval of JAKI are limited. To investigate the persistence and drug survival of different (b/tsDMARDs) in patients with RA based on real-world data from German outpatients. We performed a retrospective analysis of RA patients in the German RHADAR database who received a newly prescribed therapy with a b/tsDMARD between January 15, 2015 and October 17, 2023. To compare drug survival, we used Cox regression analyses adjusted for age, sex and disease duration. We included 4678 patients (79.9% female, mean age 58.7 years, mean disease duration 11.7 years). TNFi (47.8%) and JAKi (29.4%) were most frequently prescribed. The five-year drug survival rate was highest for JAKi (68.3%), followed by TNFi (58.6%), IL-6i (58.6%), abatacept (55.0%), and rituximab (53.3%). Compared to JAKi, Cox regression showed a higher discontinuation risk for rituximab (HR 1.36},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept, interleukin-6 inhibitors (IL-6i) and tumor necrosis factor inhibitors (TNFi). Real-world data regarding treatment persistence and drug survival in the time period following the approval of JAKI are limited. To investigate the persistence and drug survival of different (b/tsDMARDs) in patients with RA based on real-world data from German outpatients. We performed a retrospective analysis of RA patients in the German RHADAR database who received a newly prescribed therapy with a b/tsDMARD between January 15, 2015 and October 17, 2023. To compare drug survival, we used Cox regression analyses adjusted for age, sex and disease duration. We included 4678 patients (79.9% female, mean age 58.7 years, mean disease duration 11.7 years). TNFi (47.8%) and JAKi (29.4%) were most frequently prescribed. The five-year drug survival rate was highest for JAKi (68.3%), followed by TNFi (58.6%), IL-6i (58.6%), abatacept (55.0%), and rituximab (53.3%). Compared to JAKi, Cox regression showed a higher discontinuation risk for rituximab (HR 1.36 |
Albrecht, Alexander; Taubmann, Jule; Minopoulou, Ioanna; Hatscher, Lukas; Kleinert, Stefan; Mühlensiepen, Felix; Welcker, Martin; Leipe, Jan; Schulz, Nils; Klemm, Philipp; Hueber, Axel; Schett, Georg; Kuhn, Sebastian; Labinsky, Hannah; Knitza, Johannes: Real-World-Evidence of Digital Health Applications (DiGAs) in Rheumatology: Insights from the DiGAReal Registry. In: Rheumatol Ther, Bd. 12, Nr. 2, S. 267–282, 2025, ISSN: 2198-6576. @article{pmid39836353,
title = {Real-World-Evidence of Digital Health Applications (DiGAs) in Rheumatology: Insights from the DiGAReal Registry},
author = {Alexander Albrecht and Jule Taubmann and Ioanna Minopoulou and Lukas Hatscher and Stefan Kleinert and Felix Mühlensiepen and Martin Welcker and Jan Leipe and Nils Schulz and Philipp Klemm and Axel Hueber and Georg Schett and Sebastian Kuhn and Hannah Labinsky and Johannes Knitza},
doi = {10.1007/s40744-025-00744-y},
issn = {2198-6576},
year = {2025},
date = {2025-04-01},
journal = {Rheumatol Ther},
volume = {12},
number = {2},
pages = {267–282},
abstract = {INTRODUCTION: Prescribable digital health applications (DiGAs) present scalable solutions to improve patient self-management in rheumatology, however real-world evidence is scarce. Therefore, we aimed to assess the effectiveness, usage, and usability of DiGAs prescribed by rheumatologists, as well as patient satisfaction.
METHODS: The DiGAReal registry includes adult patients with rheumatic conditions who received a DiGA prescription. Data at baseline (T0) and the 3-month follow-up (T1) were collected through electronic questionnaires. Study outcomes included DiGA-specific outcome assessments as well as generic outcome assessments, including the Patient Global Impression of Change (PGIC), Patient Activation Measure (PAM®), and the German Telehealth Usability and Utility Short Questionnaire (TUUSQ). Changes between T0 and T1 were analyzed using descriptive statistics and paired tests. RESULTS: A total of 191 patients were included between June 2022 and April 2023. Of these, 127 completed the 3-month follow-up, and 114 reported using the prescribed DiGA, with 66% reporting weekly use and 15% completing the full DiGA program. The most commonly prescribed DiGAs targeted pain management (53%). Symptom improvement was reported by 51% of patients using a DiGA, with significant reductions in exhaustion levels (p = 0.03). Significant DiGA-specific improvements were observed for DiGAs addressing back pain (p = 0.05) and insomnia (p = 0.006). However, no overall significant changes were detected in patient activation, health literacy, pain, overall health, or disease activity. Back pain and weight management DiGAs were the most effective, frequently used, and best-rated DiGAs, with symptom improvements reported by 50% to 82% of patients.
CONCLUSION: The findings suggest that DiGAs can improve symptom management in rheumatic patients, especially for conditions like back pain and weight control. Further real-world evidence is needed and may support value-based digital health efforts and reimbursement frameworks.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
INTRODUCTION: Prescribable digital health applications (DiGAs) present scalable solutions to improve patient self-management in rheumatology, however real-world evidence is scarce. Therefore, we aimed to assess the effectiveness, usage, and usability of DiGAs prescribed by rheumatologists, as well as patient satisfaction.
METHODS: The DiGAReal registry includes adult patients with rheumatic conditions who received a DiGA prescription. Data at baseline (T0) and the 3-month follow-up (T1) were collected through electronic questionnaires. Study outcomes included DiGA-specific outcome assessments as well as generic outcome assessments, including the Patient Global Impression of Change (PGIC), Patient Activation Measure (PAM®), and the German Telehealth Usability and Utility Short Questionnaire (TUUSQ). Changes between T0 and T1 were analyzed using descriptive statistics and paired tests. RESULTS: A total of 191 patients were included between June 2022 and April 2023. Of these, 127 completed the 3-month follow-up, and 114 reported using the prescribed DiGA, with 66% reporting weekly use and 15% completing the full DiGA program. The most commonly prescribed DiGAs targeted pain management (53%). Symptom improvement was reported by 51% of patients using a DiGA, with significant reductions in exhaustion levels (p = 0.03). Significant DiGA-specific improvements were observed for DiGAs addressing back pain (p = 0.05) and insomnia (p = 0.006). However, no overall significant changes were detected in patient activation, health literacy, pain, overall health, or disease activity. Back pain and weight management DiGAs were the most effective, frequently used, and best-rated DiGAs, with symptom improvements reported by 50% to 82% of patients.
CONCLUSION: The findings suggest that DiGAs can improve symptom management in rheumatic patients, especially for conditions like back pain and weight control. Further real-world evidence is needed and may support value-based digital health efforts and reimbursement frameworks. |
Volkmar, Alina; Decken, Cay-Benedict; Kleinert, Stefan; Karberg, Kirsten; Gauler, Georg; Klennert, Michael; Klennert, Jana; Aries, Peer Malte; Froschauer, Sonja; Wildenhain, Sarah; Muth, Theresia; Späthling-Mestekemper, Susanna; Kuhn, Christoph; Vorbrüggen, Wolfgang; Welcker, Martin; Bartz-Bazzanella, Peter; Englbrecht, Matthias: Potential of digital applications for self-management and other outcomes in inflammatory rheumatic diseases: a systematic literature review. In: Front Med (Lausanne), Bd. 12, S. 1617151, 2025, ISSN: 2296-858X. @article{pmid40703305,
title = {Potential of digital applications for self-management and other outcomes in inflammatory rheumatic diseases: a systematic literature review},
author = {Alina Volkmar and Cay-Benedict Decken and Stefan Kleinert and Kirsten Karberg and Georg Gauler and Michael Klennert and Jana Klennert and Peer Malte Aries and Sonja Froschauer and Sarah Wildenhain and Theresia Muth and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Peter Bartz-Bazzanella and Matthias Englbrecht},
doi = {10.3389/fmed.2025.1617151},
issn = {2296-858X},
year = {2025},
date = {2025-01-01},
journal = {Front Med (Lausanne)},
volume = {12},
pages = {1617151},
abstract = {INTRODUCTION: Inflammatory rheumatic diseases (IRDs) are chronic autoimmune conditions affecting the musculoskeletal system, leading to pain, disability, and reduced quality of life. Despite advances in medical treatments, barriers such as delayed diagnosis, workforce shortages, and low adherence to self-management strategies remain critical challenges. Digital health applications are emerging as promising tools to enhance disease management. The aim of this study was to conduct a systematic literature review (SLR) to evaluate self-care outcomes associated with digital health applications in IRDs.
METHODS: We conducted a systematic literature review according to PRISMA guidelines across four electronic databases (PubMed, Embase, CINAHL, Cochrane) from inception to July 2024. Randomized controlled trials (RCTs) and systematic reviews focusing on digital interventions to promote self-management and self-care in individuals with IRDs were included. Key outcomes were extracted and the quality of the included studies was assessed using the Critical Appraisal Skills Programme (CASP) checklist.
RESULTS: Fifteen RCTs with a total of 1912 participants were analyzed. Primary outcomes, including self-management/self-care, showed mixed results. Some studies demonstrated significant improvements in self-efficacy, pain reduction, depression/anxiety symptoms, and physical function, while others showed no notable changes. Secondary outcomes, including disease activity and medication adherence, revealed heterogeneous findings. Variability in study design, sample size, and intervention duration posed challenges for drawing definitive conclusions about the effectiveness of digital interventions.
DISCUSSION: Digital health applications show promise as cost-effective and scalable solutions to complement standard IRD care by empowering patients in their disease management. However, significant heterogeneity and limited generalizability highlight the need for more robust and long-term research to validate the efficacy of specific tools and identify best options for improving outcomes. Tailored digital interventions could bridge the gap in care for IRD patients and support their autonomy.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
INTRODUCTION: Inflammatory rheumatic diseases (IRDs) are chronic autoimmune conditions affecting the musculoskeletal system, leading to pain, disability, and reduced quality of life. Despite advances in medical treatments, barriers such as delayed diagnosis, workforce shortages, and low adherence to self-management strategies remain critical challenges. Digital health applications are emerging as promising tools to enhance disease management. The aim of this study was to conduct a systematic literature review (SLR) to evaluate self-care outcomes associated with digital health applications in IRDs.
METHODS: We conducted a systematic literature review according to PRISMA guidelines across four electronic databases (PubMed, Embase, CINAHL, Cochrane) from inception to July 2024. Randomized controlled trials (RCTs) and systematic reviews focusing on digital interventions to promote self-management and self-care in individuals with IRDs were included. Key outcomes were extracted and the quality of the included studies was assessed using the Critical Appraisal Skills Programme (CASP) checklist.
RESULTS: Fifteen RCTs with a total of 1912 participants were analyzed. Primary outcomes, including self-management/self-care, showed mixed results. Some studies demonstrated significant improvements in self-efficacy, pain reduction, depression/anxiety symptoms, and physical function, while others showed no notable changes. Secondary outcomes, including disease activity and medication adherence, revealed heterogeneous findings. Variability in study design, sample size, and intervention duration posed challenges for drawing definitive conclusions about the effectiveness of digital interventions.
DISCUSSION: Digital health applications show promise as cost-effective and scalable solutions to complement standard IRD care by empowering patients in their disease management. However, significant heterogeneity and limited generalizability highlight the need for more robust and long-term research to validate the efficacy of specific tools and identify best options for improving outcomes. Tailored digital interventions could bridge the gap in care for IRD patients and support their autonomy. |
Volkmar, Alina; von der Decken, Cay-Benedict; Kleinert, Stefan; Karberg, Kirsten; Gauler, Georg; Klennert, Michael; Klennert, Jana; Aries, Peer Malte; Froschauer, Sonja; Wildenhain, Sarah; Muth, Theresia; Späthling-Mestekemper, Susanna; Kuhn, Christoph; Vorbrüggen, Wolfgang; Welcker, Martin; Bartz-Bazzanella, Peter; Englbrecht, Matthias: Potential of digital applications for self-management and other outcomes in inflammatory rheumatic diseases: a systematic literature review. In: Front Med (Lausanne), Bd. 12, S. 1617151, 2025, ISSN: 2296-858X. @article{pmid40703305b,
title = {Potential of digital applications for self-management and other outcomes in inflammatory rheumatic diseases: a systematic literature review},
author = {Alina Volkmar and Cay-Benedict von der Decken and Stefan Kleinert and Kirsten Karberg and Georg Gauler and Michael Klennert and Jana Klennert and Peer Malte Aries and Sonja Froschauer and Sarah Wildenhain and Theresia Muth and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Peter Bartz-Bazzanella and Matthias Englbrecht},
doi = {10.3389/fmed.2025.1617151},
issn = {2296-858X},
year = {2025},
date = {2025-01-01},
journal = {Front Med (Lausanne)},
volume = {12},
pages = {1617151},
abstract = {INTRODUCTION: Inflammatory rheumatic diseases (IRDs) are chronic autoimmune conditions affecting the musculoskeletal system, leading to pain, disability, and reduced quality of life. Despite advances in medical treatments, barriers such as delayed diagnosis, workforce shortages, and low adherence to self-management strategies remain critical challenges. Digital health applications are emerging as promising tools to enhance disease management. The aim of this study was to conduct a systematic literature review (SLR) to evaluate self-care outcomes associated with digital health applications in IRDs.nnMETHODS: We conducted a systematic literature review according to PRISMA guidelines across four electronic databases (PubMed, Embase, CINAHL, Cochrane) from inception to July 2024. Randomized controlled trials (RCTs) and systematic reviews focusing on digital interventions to promote self-management and self-care in individuals with IRDs were included. Key outcomes were extracted and the quality of the included studies was assessed using the Critical Appraisal Skills Programme (CASP) checklist.nnRESULTS: Fifteen RCTs with a total of 1912 participants were analyzed. Primary outcomes, including self-management/self-care, showed mixed results. Some studies demonstrated significant improvements in self-efficacy, pain reduction, depression/anxiety symptoms, and physical function, while others showed no notable changes. Secondary outcomes, including disease activity and medication adherence, revealed heterogeneous findings. Variability in study design, sample size, and intervention duration posed challenges for drawing definitive conclusions about the effectiveness of digital interventions.nnDISCUSSION: Digital health applications show promise as cost-effective and scalable solutions to complement standard IRD care by empowering patients in their disease management. However, significant heterogeneity and limited generalizability highlight the need for more robust and long-term research to validate the efficacy of specific tools and identify best options for improving outcomes. Tailored digital interventions could bridge the gap in care for IRD patients and support their autonomy.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
INTRODUCTION: Inflammatory rheumatic diseases (IRDs) are chronic autoimmune conditions affecting the musculoskeletal system, leading to pain, disability, and reduced quality of life. Despite advances in medical treatments, barriers such as delayed diagnosis, workforce shortages, and low adherence to self-management strategies remain critical challenges. Digital health applications are emerging as promising tools to enhance disease management. The aim of this study was to conduct a systematic literature review (SLR) to evaluate self-care outcomes associated with digital health applications in IRDs.nnMETHODS: We conducted a systematic literature review according to PRISMA guidelines across four electronic databases (PubMed, Embase, CINAHL, Cochrane) from inception to July 2024. Randomized controlled trials (RCTs) and systematic reviews focusing on digital interventions to promote self-management and self-care in individuals with IRDs were included. Key outcomes were extracted and the quality of the included studies was assessed using the Critical Appraisal Skills Programme (CASP) checklist.nnRESULTS: Fifteen RCTs with a total of 1912 participants were analyzed. Primary outcomes, including self-management/self-care, showed mixed results. Some studies demonstrated significant improvements in self-efficacy, pain reduction, depression/anxiety symptoms, and physical function, while others showed no notable changes. Secondary outcomes, including disease activity and medication adherence, revealed heterogeneous findings. Variability in study design, sample size, and intervention duration posed challenges for drawing definitive conclusions about the effectiveness of digital interventions.nnDISCUSSION: Digital health applications show promise as cost-effective and scalable solutions to complement standard IRD care by empowering patients in their disease management. However, significant heterogeneity and limited generalizability highlight the need for more robust and long-term research to validate the efficacy of specific tools and identify best options for improving outcomes. Tailored digital interventions could bridge the gap in care for IRD patients and support their autonomy. |
Strunz, Patrick-Pascal; Risser, Linus Maximilian; Englbrecht, Matthias; Witte, Torsten; Froehlich, Matthias; Schmalzing, Marc; Gernert, Michael; Hueper, Sebastian; Bartz-Bazzanella, Peter; Decken, Cay; Karberg, Kirsten; Gauler, Georg; Späthling-Mestekemper, Susanna; Kuhn, Christoph; Vorbrüggen, Wolfgang; Welcker, Martin; Kleinert, Stefan: Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study. In: Frontiers in Immunology, Bd. 15, 2024, ISSN: 1664-3224. @article{RN10367,
title = {Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study},
author = {Patrick-Pascal Strunz and Linus Maximilian Risser and Matthias Englbrecht and Torsten Witte and Matthias Froehlich and Marc Schmalzing and Michael Gernert and Sebastian Hueper and Peter Bartz-Bazzanella and Cay Decken and Kirsten Karberg and Georg Gauler and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Stefan Kleinert},
doi = {10.3389/fimmu.2024.1445680},
issn = {1664-3224},
year = {2024},
date = {2024-01-01},
journal = {Frontiers in Immunology},
volume = {15},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Fröhlich, Matthias; Schmalzing, Marc; Stoerk, Stefan; Gernert, Michael; Purucker, Hanna; Kleinert, Stefan; Breunig, Margret; Strunz, Patrick P.; Labinsky, Hannah; Heuschmann, Peter U.; Rücker, Viktoria; Morbach, Caroline: Long-term cardio-vascular risk in patients with rheumatic diseases – Results of a 17 year Follow Up study [abstract]. In: Ann Rheum Dis, Bd. 83, S. 1153, 2024. @article{RN10337,
title = {Long-term cardio-vascular risk in patients with rheumatic diseases – Results of a 17 year Follow Up study [abstract]},
author = {Matthias Fröhlich and Marc Schmalzing and Stefan Stoerk and Michael Gernert and Hanna Purucker and Stefan Kleinert and Margret Breunig and Patrick P. Strunz and Hannah Labinsky and Peter U. Heuschmann and Viktoria Rücker and Caroline Morbach},
doi = {10.1136/annrheumdis-2024-eular.4323},
year = {2024},
date = {2024-01-01},
journal = {Ann Rheum Dis},
volume = {83},
pages = {1153},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Schuch, F.; Rapp, P.; Ronneberger, M.; Wendler, J.; Sternad, P.; Popp, F.; Bartz-Bazzanella, P.; Decken, C.; Karberg, K.; Gauler, G.; Wurth, P.; Spathling-Mestekemper, S.; Kuhn, C.; Vorbruggen, W.; Welcker, M.: Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices. In: Rheumatol Int, Bd. 44, Nr. 4, S. 653-661, 2024, ISSN: 1437-160X (Electronic)
0172-8172 (Linking). @article{RN10322b,
title = {Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices},
author = {S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and M. Welcker},
url = {https://www.ncbi.nlm.nih.gov/pubmed/37805981},
doi = {10.1007/s00296-023-05463-7},
issn = {1437-160X (Electronic)
0172-8172 (Linking)},
year = {2024},
date = {2024-01-01},
journal = {Rheumatol Int},
volume = {44},
number = {4},
pages = {653-661},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Rech, J.; Tascilar, K.; Hagen, M.; Kleyer, A.; Manger, B.; Schoenau, V.; Hueber, A. J.; Kleinert, S.; Baraliakos, X.; Braun, J.; Kiltz, U.; Fleck, M.; Rubbert-Roth, A.; Kofler, D. M.; Behrens, F.; Feuchtenberger, M.; Zaenker, M.; Voll, R.; Venhoff, N.; Thiel, J.; Glaser, C.; Feist, E.; Burmester, G. R.; Karberg, K.; Strunk, J.; Canete, J. D.; Senolt, L.; Filkova, M.; Naredo, E.; Largo, R.; Kronke, G.; D'Agostino, M. A.; Ostergaard, M.; Schett, G.: Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. In: Lancet, Bd. 403, Nr. 10429, S. 850-859, 2024, ISSN: 1474-547X (Electronic)
0140-6736 (Linking). @article{RN10334,
title = {Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial},
author = {J. Rech and K. Tascilar and M. Hagen and A. Kleyer and B. Manger and V. Schoenau and A. J. Hueber and S. Kleinert and X. Baraliakos and J. Braun and U. Kiltz and M. Fleck and A. Rubbert-Roth and D. M. Kofler and F. Behrens and M. Feuchtenberger and M. Zaenker and R. Voll and N. Venhoff and J. Thiel and C. Glaser and E. Feist and G. R. Burmester and K. Karberg and J. Strunk and J. D. Canete and L. Senolt and M. Filkova and E. Naredo and R. Largo and G. Kronke and M. A. D'Agostino and M. Ostergaard and G. Schett},
url = {https://www.ncbi.nlm.nih.gov/pubmed/38364841},
doi = {10.1016/S0140-6736(23)02650-8},
issn = {1474-547X (Electronic)
0140-6736 (Linking)},
year = {2024},
date = {2024-01-01},
journal = {Lancet},
volume = {403},
number = {10429},
pages = {850-859},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Strunz, P. P.; Englbrecht, M.; Risser, L. M.; Witte, T.; Froehlich, M.; Schmalzing, M.; Gernert, M.; Schmieder, A.; Bartz-Bazzanella, P.; Decken, C.; Karberg, K.; Gauler, G.; Wurth, P.; Spathling-Mestekemper, S.; Kuhn, C.; Vorbruggen, W.; Heck, J.; Welcker, M.; Kleinert, S.: Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database. In: Front Immunol, Bd. 15, S. 1395968, 2024, ISSN: 1664-3224 (Electronic)
1664-3224 (Linking), (Strunz, Patrick-Pascal
Englbrecht, Matthias
Risser, Linus Maximilian
Witte, Torsten
Froehlich, Matthias
Schmalzing, Marc
Gernert, Michael
Schmieder, Astrid
Bartz-Bazzanella, Peter
von der Decken, Cay
Karberg, Kirsten
Gauler, Georg
Wurth, Patrick
Spathling-Mestekemper, Susanna
Kuhn, Christoph
Vorbruggen, Wolfgang
Heck, Johannes
Welcker, Martin
Kleinert, Stefan
eng
Switzerland
2024/06/07
Front Immunol. 2024 May 23;15:1395968. doi: 10.3389/fimmu.2024.1395968. eCollection 2024.). @article{RN10351,
title = {Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database},
author = {P. P. Strunz and M. Englbrecht and L. M. Risser and T. Witte and M. Froehlich and M. Schmalzing and M. Gernert and A. Schmieder and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and J. Heck and M. Welcker and S. Kleinert},
url = {https://www.ncbi.nlm.nih.gov/pubmed/38846940},
doi = {10.3389/fimmu.2024.1395968},
issn = {1664-3224 (Electronic)
1664-3224 (Linking)},
year = {2024},
date = {2024-01-01},
journal = {Front Immunol},
volume = {15},
pages = {1395968},
abstract = {OBJECTIVE: Treatment options with disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) have evolved over recent years. In addition to Janus kinase inhibitors (JAKi), four classes of biologic DMARDs (bDMARDs; interleukin [IL]-23 inhibitors [IL-23i], IL-12/23 inhibitors [IL-12/23i], tumor necrosis factor inhibitors [TNFi], and IL-17 inhibitors [IL-17i]) are currently approved for moderate to severe PsA treatment. There is minimal evidence of the persistence of these drugs among PsA outpatients in a real-world scenario during the period following the approval of JAKi. Therefore, we aimed to analyze the drug survival rates of biologic and JAKi therapies among German PsA outpatients during routine clinical care. METHODS: We retrospectively analyzed PsA patients with a new prescription for a biologic or JAKi in the RHADAR database between January 2015 and October 2023. Kaplan-Meier Curves and Cox regression modelling were used to compare drug survival rates. RESULTS: 1352 new prescriptions with bDMARDs (IL-12/23i [n=50], IL-23i [n=31], TNFi [n=774], IL-17i [n=360]) or JAKi (n=137) were identified. The 5-year drug survival rate was 67.8% for IL-17i, 62.3% for TNFi, 53.3% for JAKi, and 46.0% for IL-12/23i. Discontinuation probabilities for JAKi and IL-12/23i were significantly higher compared with TNFi (JAKi hazard ratio [HR] 1.66, [95% CI 1.23-2.24]},
note = {Strunz, Patrick-Pascal
Englbrecht, Matthias
Risser, Linus Maximilian
Witte, Torsten
Froehlich, Matthias
Schmalzing, Marc
Gernert, Michael
Schmieder, Astrid
Bartz-Bazzanella, Peter
von der Decken, Cay
Karberg, Kirsten
Gauler, Georg
Wurth, Patrick
Spathling-Mestekemper, Susanna
Kuhn, Christoph
Vorbruggen, Wolfgang
Heck, Johannes
Welcker, Martin
Kleinert, Stefan
eng
Switzerland
2024/06/07
Front Immunol. 2024 May 23;15:1395968. doi: 10.3389/fimmu.2024.1395968. eCollection 2024.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
OBJECTIVE: Treatment options with disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) have evolved over recent years. In addition to Janus kinase inhibitors (JAKi), four classes of biologic DMARDs (bDMARDs; interleukin [IL]-23 inhibitors [IL-23i], IL-12/23 inhibitors [IL-12/23i], tumor necrosis factor inhibitors [TNFi], and IL-17 inhibitors [IL-17i]) are currently approved for moderate to severe PsA treatment. There is minimal evidence of the persistence of these drugs among PsA outpatients in a real-world scenario during the period following the approval of JAKi. Therefore, we aimed to analyze the drug survival rates of biologic and JAKi therapies among German PsA outpatients during routine clinical care. METHODS: We retrospectively analyzed PsA patients with a new prescription for a biologic or JAKi in the RHADAR database between January 2015 and October 2023. Kaplan-Meier Curves and Cox regression modelling were used to compare drug survival rates. RESULTS: 1352 new prescriptions with bDMARDs (IL-12/23i [n=50], IL-23i [n=31], TNFi [n=774], IL-17i [n=360]) or JAKi (n=137) were identified. The 5-year drug survival rate was 67.8% for IL-17i, 62.3% for TNFi, 53.3% for JAKi, and 46.0% for IL-12/23i. Discontinuation probabilities for JAKi and IL-12/23i were significantly higher compared with TNFi (JAKi hazard ratio [HR] 1.66, [95% CI 1.23-2.24] |
Strunz, P. P.; Englbrecht, M.; Risser, L. M.; Witte, T.; Froehlich, M.; Schmalzing, M.; Gernert, M.; Schmieder, A.; Bartz-Bazzanella, P.; Decken, C.; Karberg, K.; Gauler, G.; Wurth, P.; Spathling-Mestekemper, S.; Kuhn, C.; Vorbruggen, W.; Heck, J.; Welcker, M.; Kleinert, S.: Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network. In: Rheumatol Int, 2024, ISSN: 1437-160X (Electronic)
0172-8172 (Linking), (Strunz, Patrick-Pascal
Englbrecht, Matthias
Risser, Linus Maximilian
Witte, Torsten
Froehlich, Matthias
Schmalzing, Marc
Gernert, Michael
Schmieder, Astrid
Bartz-Bazzanella, Peter
von der Decken, Cay
Karberg, Kirsten
Gauler, Georg
Wurth, Patrick
Spathling-Mestekemper, Susanna
Kuhn, Christoph
Vorbruggen, Wolfgang
Heck, Johannes
Welcker, Martin
Kleinert, Stefan
eng
Germany
2024/08/13
Rheumatol Int. 2024 Aug 13. doi: 10.1007/s00296-024-05671-9.). @article{RN10366,
title = {Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network},
author = {P. P. Strunz and M. Englbrecht and L. M. Risser and T. Witte and M. Froehlich and M. Schmalzing and M. Gernert and A. Schmieder and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and J. Heck and M. Welcker and S. Kleinert},
url = {https://www.ncbi.nlm.nih.gov/pubmed/39136784},
doi = {10.1007/s00296-024-05671-9},
issn = {1437-160X (Electronic)
0172-8172 (Linking)},
year = {2024},
date = {2024-01-01},
journal = {Rheumatol Int},
abstract = {In recent years Janus kinase inhibitors (JAKi) have joined tumor necrosis factor inhibitors (TNFi) and interleukin (IL)-17 inhibitors (IL-17i) as approved disease modifying anti-rheumatic drugs (DMARD) for moderate to severe forms of axial spondyloarthritis (axSpA). Drug survival in axSpA patients has not been well studied in a real-world outpatient scenario since the approval of JAKi. We aimed to analyze the three drug classes based on modes of actions (MoA) for their persistence rates among German axSpA outpatients. A retrospective analysis of the RHADAR database for axSpA patients with a new initiation of TNFi, IL-17i, or JAKi treatment between January 2015 and October 2023 was conducted. Analyses included Kaplan-Meier curves and adjusted Cox regressions for drug discontinuation. 1222 new biological DMARD (TNFi [n = 954], IL-17i [n = 190]) or JAKi (n = 78) treatments were reported. The median drug survival was 31 months for TNFi, 25 for IL-17i, and 18 for JAKi. The corresponding 2-year drug survival rate was 79.6%, 72.6%, and 62.8% for TNFi, IL-17i, and JAKi, respectively. The probability for discontinuation for JAKi was significantly higher compared with TNFi (HR 1.91 [95% CI 1.22-2.99]) as well as for IL-17i compared with TNFi (HR 1.43 [95% CI 1.02-2.01]), possibly related to more frequent use of TNFis as first-line therapy. IL-17i and JAKi discontinuation probabilities were similar. Primary non-response was the reason for drug discontinuation in most cases across all MoA. TNFi treatment might persist longer than JAKi and IL-17i in German axSpA outpatients, possibly related to more severe or refractory disease in patients with JAKi-treated or IL-17i-treated axSpA.},
note = {Strunz, Patrick-Pascal
Englbrecht, Matthias
Risser, Linus Maximilian
Witte, Torsten
Froehlich, Matthias
Schmalzing, Marc
Gernert, Michael
Schmieder, Astrid
Bartz-Bazzanella, Peter
von der Decken, Cay
Karberg, Kirsten
Gauler, Georg
Wurth, Patrick
Spathling-Mestekemper, Susanna
Kuhn, Christoph
Vorbruggen, Wolfgang
Heck, Johannes
Welcker, Martin
Kleinert, Stefan
eng
Germany
2024/08/13
Rheumatol Int. 2024 Aug 13. doi: 10.1007/s00296-024-05671-9.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
In recent years Janus kinase inhibitors (JAKi) have joined tumor necrosis factor inhibitors (TNFi) and interleukin (IL)-17 inhibitors (IL-17i) as approved disease modifying anti-rheumatic drugs (DMARD) for moderate to severe forms of axial spondyloarthritis (axSpA). Drug survival in axSpA patients has not been well studied in a real-world outpatient scenario since the approval of JAKi. We aimed to analyze the three drug classes based on modes of actions (MoA) for their persistence rates among German axSpA outpatients. A retrospective analysis of the RHADAR database for axSpA patients with a new initiation of TNFi, IL-17i, or JAKi treatment between January 2015 and October 2023 was conducted. Analyses included Kaplan-Meier curves and adjusted Cox regressions for drug discontinuation. 1222 new biological DMARD (TNFi [n = 954], IL-17i [n = 190]) or JAKi (n = 78) treatments were reported. The median drug survival was 31 months for TNFi, 25 for IL-17i, and 18 for JAKi. The corresponding 2-year drug survival rate was 79.6%, 72.6%, and 62.8% for TNFi, IL-17i, and JAKi, respectively. The probability for discontinuation for JAKi was significantly higher compared with TNFi (HR 1.91 [95% CI 1.22-2.99]) as well as for IL-17i compared with TNFi (HR 1.43 [95% CI 1.02-2.01]), possibly related to more frequent use of TNFis as first-line therapy. IL-17i and JAKi discontinuation probabilities were similar. Primary non-response was the reason for drug discontinuation in most cases across all MoA. TNFi treatment might persist longer than JAKi and IL-17i in German axSpA outpatients, possibly related to more severe or refractory disease in patients with JAKi-treated or IL-17i-treated axSpA. |
Stephan, Marlene; Tascilar, Koray; Yalcin-Mutlu, Melek; Hagen, Melanie; Haschka, Judith; Reiser, Michaela; Hartmann, Fabian; Kleyer, Arnd; Hueber, Axel J; Manger, Bernhard; Figueiredo, Camille; Cobra, Jayme Fogagnolo; Tony, Hans-Peter; Finzel, Stephanie; Kleinert, Stefan; Wendler, Jörg; Schuch, Florian; Ronneberger, Monika; Feuchtenberger, Martin; Fleck, Martin; Manger, Karin; Ochs, Wolfgang; Schmitt-Haendle, Matthias; Lorenz, Hannes Martin; Nüsslein, Hubert; Alten, Rieke; Henes, Joerg; Krüger, Klaus; Schett, Georg; Rech, Jürgen: Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial. In: J Clin Med, Bd. 12, Nr. 11, 2023, ISSN: 2077-0383. @article{pmid37297917,
title = {Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial},
author = {Marlene Stephan and Koray Tascilar and Melek Yalcin-Mutlu and Melanie Hagen and Judith Haschka and Michaela Reiser and Fabian Hartmann and Arnd Kleyer and Axel J Hueber and Bernhard Manger and Camille Figueiredo and Jayme Fogagnolo Cobra and Hans-Peter Tony and Stephanie Finzel and Stefan Kleinert and Jörg Wendler and Florian Schuch and Monika Ronneberger and Martin Feuchtenberger and Martin Fleck and Karin Manger and Wolfgang Ochs and Matthias Schmitt-Haendle and Hannes Martin Lorenz and Hubert Nüsslein and Rieke Alten and Joerg Henes and Klaus Krüger and Georg Schett and Jürgen Rech},
doi = {10.3390/jcm12113723},
issn = {2077-0383},
year = {2023},
date = {2023-05-01},
journal = {J Clin Med},
volume = {12},
number = {11},
abstract = {Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in physical function as some patients may relapse and face increased disease activity. Here, we analyzed the impact of tapering or stopping DMARD treatment on the physical function of RA patients. The study was a post hoc analysis of physical functional worsening for 282 patients with RA in sustained remission tapering and stopping DMARD treatment in the prospective randomized RETRO study. HAQ and DAS-28 scores were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Patients were followed over 1 year, and HAQ and DAS-28 scores were evaluated every 3 months. The effect of treatment reduction strategy on functional worsening was assessed in a recurrent-event Cox regression model with a study-group (control, taper, and taper/stop) as the predictor. Two-hundred and eighty-two patients were analyzed. In 58 patients, functional worsening was observed. The incidences suggest a higher probability of functional worsening in patients tapering and/or stopping DMARDs, which is likely due to higher relapse rates in these individuals. At the end of the study, however, functional worsening was similar among the groups. Point estimates and survival curves show that the decline in functionality according to HAQ after tapering or discontinuation of DMARDs in RA patients with stable remission is associated with recurrence, but not with an overall functional decline.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in physical function as some patients may relapse and face increased disease activity. Here, we analyzed the impact of tapering or stopping DMARD treatment on the physical function of RA patients. The study was a post hoc analysis of physical functional worsening for 282 patients with RA in sustained remission tapering and stopping DMARD treatment in the prospective randomized RETRO study. HAQ and DAS-28 scores were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Patients were followed over 1 year, and HAQ and DAS-28 scores were evaluated every 3 months. The effect of treatment reduction strategy on functional worsening was assessed in a recurrent-event Cox regression model with a study-group (control, taper, and taper/stop) as the predictor. Two-hundred and eighty-two patients were analyzed. In 58 patients, functional worsening was observed. The incidences suggest a higher probability of functional worsening in patients tapering and/or stopping DMARDs, which is likely due to higher relapse rates in these individuals. At the end of the study, however, functional worsening was similar among the groups. Point estimates and survival curves show that the decline in functionality according to HAQ after tapering or discontinuation of DMARDs in RA patients with stable remission is associated with recurrence, but not with an overall functional decline. |
Kleinert, Stefan; Rapp, Praxedis; Schuch, Florian; Ronneberger, Monika; Wendler, Joerg; Sternad, Patrizia; Popp, Florian; Bartz-Bazzanella, Peter; Decken, Cay; Karberg, Kirsten; Gauler, Georg; Wurth, Patrick; Späthling-Mestekemper, Susanna; Kuhn, Christoph; Vorbrüggen, Wolfgang; Welcker, Martin: Röntgenologische versus non-röntgenologische axiale Spondyloarthritis - Auch ein Real-World-Klassifikation. In: Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 2023. @article{RN10244,
title = {Röntgenologische versus non-röntgenologische axiale Spondyloarthritis - Auch ein Real-World-Klassifikation},
author = {Stefan Kleinert and Praxedis Rapp and Florian Schuch and Monika Ronneberger and Joerg Wendler and Patrizia Sternad and Florian Popp and Peter Bartz-Bazzanella and Cay Decken and Kirsten Karberg and Georg Gauler and Patrick Wurth and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker},
doi = {https://dx.doi.org/10.3205/23dgrh184},
year = {2023},
date = {2023-01-01},
journal = {Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Welcker, Martin; Klennert, Michael; Aries, Peer; Bartz-Bazzanella, Peter; Decken, Cay Von; Engelbrecht, Matthias; Gauler, Georg; Hornig, Johannes; Karberg, Kirsten; Kuhn, Christoph; Schuch, Florian; Späthling-Mestekemper, Susanna; Vorbrüggen, Wolfgang; Wurth, Patrick; Muth, Theresia; Froschauer-Häfele, Sonja; Mühlensiepen, Felix; Popp, Florian; Burigk, Kristin; Kladny, Heike; Kleinert, Stefan: Eine Applikation für die rheumatologische Versorgung: RheCORD. In: Aktuelle Rheumatologie, Bd. 48, Nr. 04, S. 263-269, 2023, ISSN: 0341-051X
1438-9940. @article{RN10336,
title = {Eine Applikation für die rheumatologische Versorgung: RheCORD},
author = {Martin Welcker and Michael Klennert and Peer Aries and Peter Bartz-Bazzanella and Cay Von Decken and Matthias Engelbrecht and Georg Gauler and Johannes Hornig and Kirsten Karberg and Christoph Kuhn and Florian Schuch and Susanna Späthling-Mestekemper and Wolfgang Vorbrüggen and Patrick Wurth and Theresia Muth and Sonja Froschauer-Häfele and Felix Mühlensiepen and Florian Popp and Kristin Burigk and Heike Kladny and Stefan Kleinert},
url = {http://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2113-5577},
doi = {10.1055/a-2113-5577},
issn = {0341-051X
1438-9940},
year = {2023},
date = {2023-01-01},
journal = {Aktuelle Rheumatologie},
volume = {48},
number = {04},
pages = {263-269},
abstract = {Heutzutage haben medizinische Gesundheits-Applikationen (Apps) einen zunehmenden Stellenwert. Auf nahezu jedem neuen Smartphone sind Gesundheits-Applikationen installiert. RheCORD, eine medizinische Applikation in der Rheumatologie, wird im Folgenden beschrieben und im medizinischen Kontext bewertet. Einsatzmöglichkeiten,Vorteile und Limitationen werden beschrieben.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Heutzutage haben medizinische Gesundheits-Applikationen (Apps) einen zunehmenden Stellenwert. Auf nahezu jedem neuen Smartphone sind Gesundheits-Applikationen installiert. RheCORD, eine medizinische Applikation in der Rheumatologie, wird im Folgenden beschrieben und im medizinischen Kontext bewertet. Einsatzmöglichkeiten,Vorteile und Limitationen werden beschrieben. |
Kleinert, S.; Schuch, F.; Rapp, P.; Ronneberger, M.; Wendler, J.; Sternad, P.; Popp, F.; Bartz-Bazzanella, P.; Decken, C.; Karberg, K.; Gauler, G.; Wurth, P.; Spathling-Mestekemper, S.; Kuhn, C.; Englbrecht, M.; Vorbruggen, W.; Adler, G.; Welcker, M.: Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis. In: Rheumatol Int, Bd. 43, Nr. 1, S. 89-97, 2023, ISSN: 1437-160X (Electronic)
0172-8172 (Linking). @article{RN10032,
title = {Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis},
author = {S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and M. Englbrecht and W. Vorbruggen and G. Adler and M. Welcker},
url = {https://www.ncbi.nlm.nih.gov/pubmed/36441274},
doi = {10.1007/s00296-022-05248-4},
issn = {1437-160X (Electronic)
0172-8172 (Linking)},
year = {2023},
date = {2023-01-01},
journal = {Rheumatol Int},
volume = {43},
number = {1},
pages = {89-97},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Berr, K.; Tizek, L.; Schielein, M. C.; Welcker, M.; Knitza, J.; Kleinert, S.; Zink, A.: Analyzing web searches for axial spondyloarthritis in Germany: a novel approach to exploring interests and unmet needs. In: Rheumatol Int, 2023, ISSN: 1437-160X (Electronic)
0172-8172 (Linking). @article{RN10038,
title = {Analyzing web searches for axial spondyloarthritis in Germany: a novel approach to exploring interests and unmet needs},
author = {K. Berr and L. Tizek and M. C. Schielein and M. Welcker and J. Knitza and S. Kleinert and A. Zink},
url = {https://www.ncbi.nlm.nih.gov/pubmed/36640175
https://link.springer.com/content/pdf/10.1007/s00296-023-05273-x.pdf},
doi = {10.1007/s00296-023-05273-x},
issn = {1437-160X (Electronic)
0172-8172 (Linking)},
year = {2023},
date = {2023-01-01},
journal = {Rheumatol Int},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Burigk, K.; Baltrusch, S.; Ronneberger, M.; Rapp, P.; Wendler, J.; Schuch, F.; Welcker, M.; Decken, C.; Bartz-Bazzanella, P.; Vorbrüggen, W.: RhePORT – Effizienz hinsichtlich personeller Ressourcen und Patientenselektion – Bewährung im Praxisalltag!. In: Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 2023. @article{RN10245,
title = {RhePORT – Effizienz hinsichtlich personeller Ressourcen und Patientenselektion – Bewährung im Praxisalltag!},
author = {S. Kleinert and K. Burigk and S. Baltrusch and M. Ronneberger and P. Rapp and J. Wendler and F. Schuch and M. Welcker and C. Decken and P. Bartz-Bazzanella and W. Vorbrüggen},
doi = {https://dx.doi.org/10.3205/23dgrh236},
year = {2023},
date = {2023-01-01},
journal = {Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Stephan, M.; Tascilar, K.; Yalcin-Mutlu, M.; Hagen, M.; Haschka, J.; Reiser, M.; Hartmann, F.; Kleyer, A.; Hueber, A. J.; Manger, B.; Figueiredo, C.; Cobra, J. F.; Tony, H. P.; Finzel, S.; Kleinert, S.; Wendler, J.; Schuch, F.; Ronneberger, M.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Lorenz, H. M.; Nüsslein, H.; Alten, R.; Henes, J.; Krüger, K.; Schett, G.; Rech, J.: Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial. In: J Clin Med, Bd. 12, Nr. 11, 2023, ISSN: 2077-0383 (Print)
2077-0383. @article{RN10321,
title = {Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial},
author = {M. Stephan and K. Tascilar and M. Yalcin-Mutlu and M. Hagen and J. Haschka and M. Reiser and F. Hartmann and A. Kleyer and A. J. Hueber and B. Manger and C. Figueiredo and J. F. Cobra and H. P. Tony and S. Finzel and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nüsslein and R. Alten and J. Henes and K. Krüger and G. Schett and J. Rech},
doi = {10.3390/jcm12113723},
issn = {2077-0383 (Print)
2077-0383},
year = {2023},
date = {2023-01-01},
journal = {J Clin Med},
volume = {12},
number = {11},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Schuch, F.; Rapp, P.; Ronneberger, M.; Wendler, J.; Sternad, P.; Popp, F.; Bartz-Bazzanella, P.; Decken, C.; Karberg, K.; Gauler, G.; Wurth, P.; Spathling-Mestekemper, S.; Kuhn, C.; Vorbruggen, W.; Welcker, M.: Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices. In: Rheumatol Int, 2023, ISSN: 1437-160X (Electronic) 0172-8172 (Linking). @article{RN10322,
title = {Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices},
author = {S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and M. Welcker},
url = {https://www.ncbi.nlm.nih.gov/pubmed/37805981},
doi = {10.1007/s00296-023-05463-7},
issn = {1437-160X (Electronic) 0172-8172 (Linking)},
year = {2023},
date = {2023-01-01},
urldate = {2023-01-01},
journal = {Rheumatol Int},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Gräf, Markus; Knitza, Johannes; Leipe, Jan; Krusche, Martin; Welcker, Martin; Kuhn, Sebastian; Mucke, Johanna; Hueber, Axel J; Hornig, Johannes; Klemm, Philipp; Kleinert, Stefan; Aries, Peer; Vuillerme, Nicolas; Simon, David; Kleyer, Arnd; Schett, Georg; Callhoff, Johanna: Comparison of physician and artificial intelligence-based symptom checker diagnostic accuracy. In: Rheumatol Int, Bd. 42, Nr. 12, S. 2167–2176, 2022, ISSN: 1437-160X. @article{pmid36087130,
title = {Comparison of physician and artificial intelligence-based symptom checker diagnostic accuracy},
author = {Markus Gräf and Johannes Knitza and Jan Leipe and Martin Krusche and Martin Welcker and Sebastian Kuhn and Johanna Mucke and Axel J Hueber and Johannes Hornig and Philipp Klemm and Stefan Kleinert and Peer Aries and Nicolas Vuillerme and David Simon and Arnd Kleyer and Georg Schett and Johanna Callhoff},
doi = {10.1007/s00296-022-05202-4},
issn = {1437-160X},
year = {2022},
date = {2022-12-01},
journal = {Rheumatol Int},
volume = {42},
number = {12},
pages = {2167–2176},
abstract = {Symptom checkers are increasingly used to assess new symptoms and navigate the health care system. The aim of this study was to compare the accuracy of an artificial intelligence (AI)-based symptom checker (Ada) and physicians regarding the presence/absence of an inflammatory rheumatic disease (IRD). In this survey study, German-speaking physicians with prior rheumatology working experience were asked to determine IRD presence/absence and suggest diagnoses for 20 different real-world patient vignettes, which included only basic health and symptom-related medical history. IRD detection rate and suggested diagnoses of participants and Ada were compared to the gold standard, the final rheumatologists' diagnosis, reported on the discharge summary report. A total of 132 vignettes were completed by 33 physicians (mean rheumatology working experience 8.8 (SD 7.1) years). Ada's diagnostic accuracy (IRD) was significantly higher compared to physicians (70 vs 54%},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Symptom checkers are increasingly used to assess new symptoms and navigate the health care system. The aim of this study was to compare the accuracy of an artificial intelligence (AI)-based symptom checker (Ada) and physicians regarding the presence/absence of an inflammatory rheumatic disease (IRD). In this survey study, German-speaking physicians with prior rheumatology working experience were asked to determine IRD presence/absence and suggest diagnoses for 20 different real-world patient vignettes, which included only basic health and symptom-related medical history. IRD detection rate and suggested diagnoses of participants and Ada were compared to the gold standard, the final rheumatologists' diagnosis, reported on the discharge summary report. A total of 132 vignettes were completed by 33 physicians (mean rheumatology working experience 8.8 (SD 7.1) years). Ada's diagnostic accuracy (IRD) was significantly higher compared to physicians (70 vs 54% |
Simon, David; Tascilar, Koray; Kleyer, Arnd; Fagni, Filippo; Krönke, Gerhard; Meder, Christine; Dietrich, Peter; Orlemann, Till; Kliem, Thorsten; Mößner, Johanna; Liphardt, Anna-Maria; Schönau, Verena; Bohr, Daniela; Schuster, Louis; Hartmann, Fabian; Leppkes, Moritz; Ramming, Andreas; Pachowsky, Milena; Schuch, Florian; Ronneberger, Monika; Kleinert, Stefan; Hueber, Axel J; Manger, Karin; Manger, Bernhard; Atreya, Raja; Berking, Carola; Sticherling, Michael; Neurath, Markus F; Schett, Georg: Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate, and longevity of the humoral immune response against SARS-CoV-2 in an unvaccinated cohort. In: Arthritis Rheumatol., Bd. 74, Nr. 5, S. 783–790, 2022. @article{Simon2022-wz,
title = {Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate, and longevity of the humoral immune response against SARS-CoV-2 in an unvaccinated cohort},
author = {David Simon and Koray Tascilar and Arnd Kleyer and Filippo Fagni and Gerhard Krönke and Christine Meder and Peter Dietrich and Till Orlemann and Thorsten Kliem and Johanna Mößner and Anna-Maria Liphardt and Verena Schönau and Daniela Bohr and Louis Schuster and Fabian Hartmann and Moritz Leppkes and Andreas Ramming and Milena Pachowsky and Florian Schuch and Monika Ronneberger and Stefan Kleinert and Axel J Hueber and Karin Manger and Bernhard Manger and Raja Atreya and Carola Berking and Michael Sticherling and Markus F Neurath and Georg Schett},
url = {https://pubmed.ncbi.nlm.nih.gov/34951137/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011429/},
year = {2022},
date = {2022-05-01},
urldate = {2022-05-01},
journal = {Arthritis Rheumatol.},
volume = {74},
number = {5},
pages = {783–790},
publisher = {Wiley},
abstract = {ÖBJECTIVE: To investigate the impact of biologic
disease-modifying antirheumatic drug (bDMARD) treatment on the
prevalence, seroconversion rate, and longevity of the humoral
immune response against SARS-CoV-2 in patients with
immune-mediated inflammatory diseases (IMIDs). METHODS:
Anti-SARS-CoV-2 IgG antibodies were measured in a prospective
cohort of health care professional controls and non-health care
controls and IMID patients receiving no treatment or receiving
treatment with conventional or biologic DMARDs during the first
and second COVID-19 waves. Regression models adjusting for age,
sex, sampling time, and exposure risk behavior were used to
calculate relative risks (RRs) of seropositivity. Seroconversion
rates were assessed in participants with polymerase chain
reaction (PCR)-positive SARS-CoV-2 infection. Antibody response
longevity was evaluated by reassessing participants who tested
positive during the first wave. RESULTS: In this study, 4,508
participants (2,869 IMID patients and 1,639 controls) were
analyzed. The unadjusted RR (0.44 [95% confidence interval
(95% CI) 0.31-0.62]) and adjusted RR (0.50 [95% CI 0.34-0.73])
for SARS-CoV-2 IgG antibodies were significantly lower in IMID
patients treated with bDMARDs compared to non-health care
controls (P < 0.001), primarily driven by treatment with tumor
necrosis factor inhibitors, interleukin-17 (IL-17) inhibitors,
and IL-23 inhibitors. Adjusted RRs for untreated IMID patients
(1.12 [95% CI 0.75-1.67]) and IMID patients receiving
conventional synthetic DMARDs (0.70 [95% CI 0.45-1.08]) were
not significantly different from non-health care controls. Lack
of seroconversion in PCR-positive participants was more common
among bDMARD-treated patients (38.7%) than in non-health care
controls (16%). Overall, 44% of positive participants lost
SARS-CoV-2 antibodies by follow-up, with higher rates in IMID
patients treated with bDMARDs (RR 2.86 [95% CI 1.43-5.74]).
CONCLUSION: IMID patients treated with bDMARDs have a lower
prevalence of SARS-CoV-2 antibodies, seroconvert less frequently
after SARS-CoV-2 infection, and may exhibit a reduced longevity
of their humoral immune response."},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
ÖBJECTIVE: To investigate the impact of biologic
disease-modifying antirheumatic drug (bDMARD) treatment on the
prevalence, seroconversion rate, and longevity of the humoral
immune response against SARS-CoV-2 in patients with
immune-mediated inflammatory diseases (IMIDs). METHODS:
Anti-SARS-CoV-2 IgG antibodies were measured in a prospective
cohort of health care professional controls and non-health care
controls and IMID patients receiving no treatment or receiving
treatment with conventional or biologic DMARDs during the first
and second COVID-19 waves. Regression models adjusting for age,
sex, sampling time, and exposure risk behavior were used to
calculate relative risks (RRs) of seropositivity. Seroconversion
rates were assessed in participants with polymerase chain
reaction (PCR)-positive SARS-CoV-2 infection. Antibody response
longevity was evaluated by reassessing participants who tested
positive during the first wave. RESULTS: In this study, 4,508
participants (2,869 IMID patients and 1,639 controls) were
analyzed. The unadjusted RR (0.44 [95% confidence interval
(95% CI) 0.31-0.62]) and adjusted RR (0.50 [95% CI 0.34-0.73])
for SARS-CoV-2 IgG antibodies were significantly lower in IMID
patients treated with bDMARDs compared to non-health care
controls (P < 0.001), primarily driven by treatment with tumor
necrosis factor inhibitors, interleukin-17 (IL-17) inhibitors,
and IL-23 inhibitors. Adjusted RRs for untreated IMID patients
(1.12 [95% CI 0.75-1.67]) and IMID patients receiving
conventional synthetic DMARDs (0.70 [95% CI 0.45-1.08]) were
not significantly different from non-health care controls. Lack
of seroconversion in PCR-positive participants was more common
among bDMARD-treated patients (38.7%) than in non-health care
controls (16%). Overall, 44% of positive participants lost
SARS-CoV-2 antibodies by follow-up, with higher rates in IMID
patients treated with bDMARDs (RR 2.86 [95% CI 1.43-5.74]).
CONCLUSION: IMID patients treated with bDMARDs have a lower
prevalence of SARS-CoV-2 antibodies, seroconvert less frequently
after SARS-CoV-2 infection, and may exhibit a reduced longevity
of their humoral immune response." |
Englbrecht, M.; Bartz-Bazzanella, P.; Decken, C.; Gauler, G.; Wurth, P.; Aries, P.; Karberg, K.; Kuhn, C.; Schuch, F.; Spathling-Mestekemper, S.; Vorbruggen, W.; Wendler, J.; Welcker, M.; Kleinert, S.: Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?. In: Front Med (Lausanne), Bd. 8, S. 748262, 2021, ISSN: 2296-858X (Print)
2296-858X (Linking). @article{RN9958,
title = {Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?},
author = {M. Englbrecht and P. Bartz-Bazzanella and C. Decken and G. Gauler and P. Wurth and P. Aries and K. Karberg and C. Kuhn and F. Schuch and S. Spathling-Mestekemper and W. Vorbruggen and J. Wendler and M. Welcker and S. Kleinert},
url = {https://www.ncbi.nlm.nih.gov/pubmed/34790678
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591045/pdf/fmed-08-748262.pdf},
doi = {10.3389/fmed.2021.748262},
issn = {2296-858X (Print)
2296-858X (Linking)},
year = {2021},
date = {2021-01-01},
journal = {Front Med (Lausanne)},
volume = {8},
pages = {748262},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.: [Data analysis in rheumatology practices : Possibilities, limitations, and results]. In: Z Rheumatol, Bd. 80, Nr. 9, S. 827-834, 2021, ISSN: 1435-1250 (Electronic)
0340-1855 (Linking). @article{RN9959,
title = {[Data analysis in rheumatology practices : Possibilities, limitations, and results]},
author = {S. Kleinert},
url = {https://www.ncbi.nlm.nih.gov/pubmed/34618210
https://link.springer.com/content/pdf/10.1007/s00393-021-01103-2.pdf},
doi = {10.1007/s00393-021-01103-2},
issn = {1435-1250 (Electronic)
0340-1855 (Linking)},
year = {2021},
date = {2021-01-01},
journal = {Z Rheumatol},
volume = {80},
number = {9},
pages = {827-834},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Bartz-Bazzanella, P.; Decken, C.; Knitza, J.; Witte, T.; Fekete, S. P.; Konitzny, M.; Zink, A.; Gauler, G.; Wurth, P.; Aries, P.; Karberg, K.; Kuhn, C.; Schuch, F.; Spathling-Mestekemper, S.; Vorbruggen, W.; Englbrecht, M.; Welcker, M.; Group, Rhadar: A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry. In: J Med Internet Res, Bd. 23, Nr. 5, S. e28164, 2021, ISSN: 1438-8871 (Electronic)
1438-8871 (Linking). @article{RN9809,
title = {A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry},
author = {S. Kleinert and P. Bartz-Bazzanella and C. Decken and J. Knitza and T. Witte and S. P. Fekete and M. Konitzny and A. Zink and G. Gauler and P. Wurth and P. Aries and K. Karberg and C. Kuhn and F. Schuch and S. Spathling-Mestekemper and W. Vorbruggen and M. Englbrecht and M. Welcker and Rhadar Group},
url = {https://www.ncbi.nlm.nih.gov/pubmed/34014170},
doi = {10.2196/28164},
issn = {1438-8871 (Electronic)
1438-8871 (Linking)},
year = {2021},
date = {2021-01-01},
journal = {J Med Internet Res},
volume = {23},
number = {5},
pages = {e28164},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Rapp, P.; Schuch, F.; Ronneberger, M.; Wendler, J.; Sternad, P.; Popp, F.; Bartz-Bazzanella, P.; Decken, C. B. Von; Karberg, K.; Gauler, G.; Wurth, P.; Spaethling-Mestekemper, S.; Kuhn, C.; Englbrecht, M.; Vorbrüggen, W.; Adler, G.; Welcker, M.: Cognitive Impairment in axial spondyloarthritis? [abstract]. In: Annals of the Rheumatic Diseases, Bd. 80, Nr. Suppl 1, S. 1274, 2021. @article{RN9667,
title = {Cognitive Impairment in axial spondyloarthritis? [abstract]},
author = {S. Kleinert and P. Rapp and F. Schuch and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. B. Von Decken and K. Karberg and G. Gauler and P. Wurth and S. Spaethling-Mestekemper and C. Kuhn and M. Englbrecht and W. Vorbrüggen and G. Adler and M. Welcker},
url = {http://ard.bmj.com/content/80/Suppl_1/1274.abstract
https://ard.bmj.com/content/annrheumdis/80/Suppl_1/1274.full.pdf},
doi = {10.1136/annrheumdis-2021-eular.1353},
year = {2021},
date = {2021-01-01},
journal = {Annals of the Rheumatic Diseases},
volume = {80},
number = {Suppl 1},
pages = {1274},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Knitza, J.; Mohn, J.; Bergmann, C.; Kampylafka, E.; Hagen, M.; Bohr, D.; Morf, H.; Araujo, E.; Englbrecht, M.; Simon, D.; Kleyer, A.; Meinderink, T.; Vorbruggen, W.; Decken, C. B.; Kleinert, S.; Ramming, A.; Distler, J. H. W.; Vuillerme, N.; Fricker, A.; Bartz-Bazzanella, P.; Schett, G.; Hueber, A. J.; Welcker, M.: Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial. In: Arthritis Res Ther, Bd. 23, Nr. 1, S. 112, 2021, ISSN: 1478-6362 (Electronic)
1478-6354 (Linking). @article{RN9671,
title = {Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial},
author = {J. Knitza and J. Mohn and C. Bergmann and E. Kampylafka and M. Hagen and D. Bohr and H. Morf and E. Araujo and M. Englbrecht and D. Simon and A. Kleyer and T. Meinderink and W. Vorbruggen and C. B. Decken and S. Kleinert and A. Ramming and J. H. W. Distler and N. Vuillerme and A. Fricker and P. Bartz-Bazzanella and G. Schett and A. J. Hueber and M. Welcker},
url = {https://www.ncbi.nlm.nih.gov/pubmed/33849654
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042673/pdf/13075_2021_Article_2498.pdf},
doi = {10.1186/s13075-021-02498-8},
issn = {1478-6362 (Electronic)
1478-6354 (Linking)},
year = {2021},
date = {2021-01-01},
journal = {Arthritis Res Ther},
volume = {23},
number = {1},
pages = {112},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Simon, D.; Tascilar, K.; Fagni, F.; Kronke, G.; Kleyer, A.; Meder, C.; Atreya, R.; Leppkes, M.; Kremer, A. E.; Ramming, A.; Pachowsky, M. L.; Schuch, F.; Ronneberger, M.; Kleinert, S.; Hueber, A. J.; Manger, K.; Manger, B.; Berking, C.; Sticherling, M.; Neurath, M. F.; Schett, G.: SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. In: Ann Rheum Dis, 2021, ISSN: 1468-2060 (Electronic)
0003-4967 (Linking). @article{RN9669,
title = {SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases},
author = {D. Simon and K. Tascilar and F. Fagni and G. Kronke and A. Kleyer and C. Meder and R. Atreya and M. Leppkes and A. E. Kremer and A. Ramming and M. L. Pachowsky and F. Schuch and M. Ronneberger and S. Kleinert and A. J. Hueber and K. Manger and B. Manger and C. Berking and M. Sticherling and M. F. Neurath and G. Schett},
url = {https://www.ncbi.nlm.nih.gov/pubmed/33958324},
doi = {10.1136/annrheumdis-2021-220461},
issn = {1468-2060 (Electronic)
0003-4967 (Linking)},
year = {2021},
date = {2021-01-01},
journal = {Ann Rheum Dis},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Schwaneck, E. C.; Renner, R.; Junker, L.; Tony, H. P.; Kleinert, S.; Gernert, M.; Schmalzing, M.; Gadeholt, O.: T cells, natural killer cells, and gammadeltaT cells in a large patient cohort with rheumatoid arthritis: influence of age and anti-rheumatic therapy. In: Scand J Rheumatol, Bd. 49, Nr. 1, S. 8-12, 2020, ISSN: 1502-7732 (Electronic)
0300-9742 (Linking). @article{RN9458,
title = {T cells, natural killer cells, and gammadeltaT cells in a large patient cohort with rheumatoid arthritis: influence of age and anti-rheumatic therapy},
author = {E. C. Schwaneck and R. Renner and L. Junker and H. P. Tony and S. Kleinert and M. Gernert and M. Schmalzing and O. Gadeholt},
url = {https://www.ncbi.nlm.nih.gov/pubmed/31556339},
doi = {10.1080/03009742.2019.1634755},
issn = {1502-7732 (Electronic)
0300-9742 (Linking)},
year = {2020},
date = {2020-01-01},
journal = {Scand J Rheumatol},
volume = {49},
number = {1},
pages = {8-12},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Simon, D.; Tascilar, K.; Kronke, G.; Kleyer, A.; Zaiss, M. M.; Heppt, F.; Meder, C.; Atreya, R.; Klenske, E.; Dietrich, P.; Abdullah, A.; Kliem, T.; Corte, G.; Morf, H.; Leppkes, M.; Kremer, A. E.; Ramming, A.; Pachowsky, M.; Schuch, F.; Ronneberger, M.; Kleinert, S.; Maier, C.; Hueber, A. J.; Manger, K.; Manger, B.; Berking, C.; Tenbusch, M.; Uberla, K.; Sticherling, M.; Neurath, M. F.; Schett, G.: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. In: Nat Commun, Bd. 11, Nr. 1, S. 3774, 2020, ISSN: 2041-1723 (Electronic)
2041-1723 (Linking). @article{RN9673,
title = {Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion},
author = {D. Simon and K. Tascilar and G. Kronke and A. Kleyer and M. M. Zaiss and F. Heppt and C. Meder and R. Atreya and E. Klenske and P. Dietrich and A. Abdullah and T. Kliem and G. Corte and H. Morf and M. Leppkes and A. E. Kremer and A. Ramming and M. Pachowsky and F. Schuch and M. Ronneberger and S. Kleinert and C. Maier and A. J. Hueber and K. Manger and B. Manger and C. Berking and M. Tenbusch and K. Uberla and M. Sticherling and M. F. Neurath and G. Schett},
url = {https://www.ncbi.nlm.nih.gov/pubmed/32709909},
doi = {10.1038/s41467-020-17703-6},
issn = {2041-1723 (Electronic)
2041-1723 (Linking)},
year = {2020},
date = {2020-01-01},
journal = {Nat Commun},
volume = {11},
number = {1},
pages = {3774},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
S, Kleinert; P, Bartz-Bazzanella; C, Decken; K, Karberg; F, Schuch; G, Gauler; P, Wurth; S, Spaethling-Mestekemper; C, Kuhn; M, Englbrecht; W, Vorbrueggen; M., Welcker: Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists [abstract]. In: Arthritis Rheumatol., Bd. 72 (suppl 10)., 2020. @article{RN9624,
title = {Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists [abstract]},
author = {Kleinert S and Bartz-Bazzanella P and Decken C and Karberg K and Schuch F and Gauler G and Wurth P and Spaethling-Mestekemper S and Kuhn C and Englbrecht M and Vorbrueggen W and Welcker M.},
year = {2020},
date = {2020-01-01},
journal = {Arthritis Rheumatol.},
volume = {72 (suppl 10).},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Englbrecht, Matthias; Alten, Rieke; Aringer, Martin; Baerwald, Christoph G.; Burkhardt, Harald; Eby, Nancy; Flacke, Jan-Paul; Fliedner, Gerhard; Henkemeier, Ulf; Hofmann, Michael W.; Kleinert, Stefan; Kneitz, Christian; Krüger, Klaus; Pohl, Christoph; Schett, Georg; Schmalzing, Marc; Tausche, Anne-Kathrin; Tony, Hans-Peter; Wendler, Jörg: New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis – Implications from the prospective multicenter VADERA II study. In: PLOS ONE, Bd. 14, Nr. 5, S. e0217412, 2019. @article{RN9063,
title = {New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis – Implications from the prospective multicenter VADERA II study},
author = {Matthias Englbrecht and Rieke Alten and Martin Aringer and Christoph G. Baerwald and Harald Burkhardt and Nancy Eby and Jan-Paul Flacke and Gerhard Fliedner and Ulf Henkemeier and Michael W. Hofmann and Stefan Kleinert and Christian Kneitz and Klaus Krüger and Christoph Pohl and Georg Schett and Marc Schmalzing and Anne-Kathrin Tausche and Hans-Peter Tony and Jörg Wendler},
url = {https://doi.org/10.1371/journal.pone.0217412},
doi = {10.1371/journal.pone.0217412},
year = {2019},
date = {2019-01-01},
journal = {PLOS ONE},
volume = {14},
number = {5},
pages = {e0217412},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, Stefan; Schuch, Florian; Rapp, Praxedis; Ronneberger, Monika; Wendler, Joerg; Englbrecht, Matthias: How many of your patients have depressive symptoms? How to assess during routine clinical practice?. In: Ann Rheum Dis, Bd. 78, S. A638, 2019. @article{RN9615,
title = {How many of your patients have depressive symptoms? How to assess during routine clinical practice?},
author = {Stefan Kleinert and Florian Schuch and Praxedis Rapp and Monika Ronneberger and Joerg Wendler and Matthias Englbrecht},
year = {2019},
date = {2019-01-01},
journal = {Ann Rheum Dis},
volume = {78},
pages = {A638},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, Stefan; Rapp, Praxedis; Ronneberger, Monika; Wendler, Joerg; Schuch, Florian: Dealing with comorbidities in rheumatoid arthritis with medical assistants. The patients’ opinion on assessment and education by medical assistants during routine clinical practice [abstract]. In: Ann Rheum Dis, Bd. 78, supplement 2, 2019. @article{RN9625,
title = {Dealing with comorbidities in rheumatoid arthritis with medical assistants. The patients’ opinion on assessment and education by medical assistants during routine clinical practice [abstract]},
author = {Stefan Kleinert and Praxedis Rapp and Monika Ronneberger and Joerg Wendler and Florian Schuch},
year = {2019},
date = {2019-01-01},
journal = {Ann Rheum Dis},
volume = {78, supplement 2},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, Stefan: Komorbiditäten und Mortalität bei Patienten mit entzündlichen Gelenkerkrankungen. In: Akt Rheumatol, Bd. 43, Nr. 02, S. 156-160, 2018, ISSN: 0341-051X. @article{RN9062,
title = {Komorbiditäten und Mortalität bei Patienten mit entzündlichen Gelenkerkrankungen},
author = {Stefan Kleinert},
url = {https://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0043-118005.pdf},
doi = {10.1055/s-0043-118005},
issn = {0341-051X},
year = {2018},
date = {2018-01-01},
journal = {Akt Rheumatol},
volume = {43},
number = {02},
pages = {156-160},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Schwaneck, E. C.; Renner, R.; Junker, L.; Einsele, H.; Gadeholt, O.; Geissinger, E.; Kleinert, S.; Gernert, M.; Tony, H. P.; Schmalzing, M.: Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients. In: Arthritis Rheumatol, Bd. 70, Nr. 12, S. 1914-1922, 2018, ISSN: 2326-5205 (Electronic)
2326-5191 (Linking). @article{RN9017,
title = {Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients},
author = {E. C. Schwaneck and R. Renner and L. Junker and H. Einsele and O. Gadeholt and E. Geissinger and S. Kleinert and M. Gernert and H. P. Tony and M. Schmalzing},
url = {https://www.ncbi.nlm.nih.gov/pubmed/29938921},
doi = {10.1002/art.40654},
issn = {2326-5205 (Electronic)
2326-5191 (Linking)},
year = {2018},
date = {2018-01-01},
journal = {Arthritis Rheumatol},
volume = {70},
number = {12},
pages = {1914-1922},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Figueiredo, Camille P; Bang, Holger; Cobra, Jayme Fogagnolo; Englbrecht, Matthias; Hueber, Axel J; Haschka, Judith; Manger, Bernhard; Kleyer, Arnd; Reiser, Michaela; Finzel, Stephanie; Tony, Hans-Peter; Kleinert, Stefan; Wendler, Joerg; Schuch, Florian; Ronneberger, Monika; Feuchtenberger, Martin; Fleck, Martin; Manger, Karin; Ochs, Wolfgang; Schmitt-Haendle, Matthias; Lorenz, Hanns-Martin; Nuesslein, Hubert; Alten, Rieke; Henes, Joerg; Krueger, Klaus; Rech, Jürgen; Schett, Georg: Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. In: Ann. Rheum. Dis., Bd. 76, Nr. 2, S. 399–407, 2017. @article{Figueiredo2017-hw,
title = {Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs},
author = {Camille P Figueiredo and Holger Bang and Jayme Fogagnolo Cobra and Matthias Englbrecht and Axel J Hueber and Judith Haschka and Bernhard Manger and Arnd Kleyer and Michaela Reiser and Stephanie Finzel and Hans-Peter Tony and Stefan Kleinert and Joerg Wendler and Florian Schuch and Monika Ronneberger and Martin Feuchtenberger and Martin Fleck and Karin Manger and Wolfgang Ochs and Matthias Schmitt-Haendle and Hanns-Martin Lorenz and Hubert Nuesslein and Rieke Alten and Joerg Henes and Klaus Krueger and Jürgen Rech and Georg Schett},
year = {2017},
date = {2017-02-01},
urldate = {2017-02-01},
journal = {Ann. Rheum. Dis.},
volume = {76},
number = {2},
pages = {399–407},
abstract = {ÖBJECTIVE: To perform a detailed analysis of the autoantibody
response against post-translationally modified proteins in
patients with rheumatoid arthritis (RA) in sustained remission
and to explore whether its composition influences the risk for
disease relapse when tapering disease modifying antirheumatic
drug (DMARD) therapy. METHODS: Immune responses against 10
citrullinated, homocitrullinated/carbamylated and acetylated
peptides, as well as unmodified vimentin (control) and cyclic
citrullinated peptide 2 (CCP2) were tested in baseline serum
samples from 94 patients of the RETRO study. Patients were
classified according to the number of autoantibody reactivities
(0-1/10, 2-5/10 and >5/10) or specificity groups (citrullination,
carbamylation and acetylation; 0-3) and tested for their risk to
develop relapses after DMARD tapering. Demographic and
disease-specific parameters were included in multivariate
logistic regression analysis for defining the role of
autoantibodies in predicting relapse. RESULTS: Patients varied in
their antimodified protein antibody response with the extremes
from recognition of no (0/10) to all antigens (10/10). Antibodies
against citrullinated vimentin (51%), acetylated ornithine (46%) and acetylated lysine (37%) were the most frequently observed subspecificities. Relapse risk significantly (p=0.011)
increased from 18% (0-1/10 reactivities) to 34% (2-5/10) and 55% (>5/10). With respect to specificity groups (0-3), relapse risk significantly (p=0.021) increased from 18% (no reactivity)
to 28%, 36% and finally to 52% with one, two or three antibody
specificity groups, respectively. CONCLUSIONS: The data suggest
that the pattern of antimodified protein antibody response
determines the risk of disease relapse in patients with RA
tapering DMARD therapy. TRIAL REGISTRATION NUMBER:
2009-015740-42; Results."},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
ÖBJECTIVE: To perform a detailed analysis of the autoantibody
response against post-translationally modified proteins in
patients with rheumatoid arthritis (RA) in sustained remission
and to explore whether its composition influences the risk for
disease relapse when tapering disease modifying antirheumatic
drug (DMARD) therapy. METHODS: Immune responses against 10
citrullinated, homocitrullinated/carbamylated and acetylated
peptides, as well as unmodified vimentin (control) and cyclic
citrullinated peptide 2 (CCP2) were tested in baseline serum
samples from 94 patients of the RETRO study. Patients were
classified according to the number of autoantibody reactivities
(0-1/10, 2-5/10 and >5/10) or specificity groups (citrullination,
carbamylation and acetylation; 0-3) and tested for their risk to
develop relapses after DMARD tapering. Demographic and
disease-specific parameters were included in multivariate
logistic regression analysis for defining the role of
autoantibodies in predicting relapse. RESULTS: Patients varied in
their antimodified protein antibody response with the extremes
from recognition of no (0/10) to all antigens (10/10). Antibodies
against citrullinated vimentin (51%), acetylated ornithine (46%) and acetylated lysine (37%) were the most frequently observed subspecificities. Relapse risk significantly (p=0.011)
increased from 18% (0-1/10 reactivities) to 34% (2-5/10) and 55% (>5/10). With respect to specificity groups (0-3), relapse risk significantly (p=0.021) increased from 18% (no reactivity)
to 28%, 36% and finally to 52% with one, two or three antibody
specificity groups, respectively. CONCLUSIONS: The data suggest
that the pattern of antimodified protein antibody response
determines the risk of disease relapse in patients with RA
tapering DMARD therapy. TRIAL REGISTRATION NUMBER:
2009-015740-42; Results." |
Albrecht, K.; Huscher, D.; Eidner, T.; Kleinert, S.; Spathling-Mestekemper, S.; Bischoff, S.; Zink, A.: [Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers]. In: Z Rheumatol, Bd. 76, Nr. 1, S. 50-57, 2017, ISSN: 1435-1250 (Electronic)
0340-1855 (Linking). @article{RN8199,
title = {[Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers]},
author = {K. Albrecht and D. Huscher and T. Eidner and S. Kleinert and S. Spathling-Mestekemper and S. Bischoff and A. Zink},
url = {https://www.ncbi.nlm.nih.gov/pubmed/27379740
https://link.springer.com/article/10.1007%2Fs00393-016-0156-5},
doi = {10.1007/s00393-016-0156-5},
issn = {1435-1250 (Electronic)
0340-1855 (Linking)},
year = {2017},
date = {2017-01-01},
journal = {Z Rheumatol},
volume = {76},
number = {1},
pages = {50-57},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Breunig, M.; Kleinert, S.; Lehmann, S.; Kneitz, C.; Feuchtenberger, M.; Tony, H. P.; Angermann, C. E.; Ertl, G.; Stork, S.: Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. In: Scand J Rheumatol, S. 1-8, 2017, ISSN: 1502-7732 (Electronic)
0300-9742 (Linking). @article{RN8877,
title = {Simple screening tools predict death and cardiovascular events in patients with rheumatic disease},
author = {M. Breunig and S. Kleinert and S. Lehmann and C. Kneitz and M. Feuchtenberger and H. P. Tony and C. E. Angermann and G. Ertl and S. Stork},
url = {https://www.ncbi.nlm.nih.gov/pubmed/28812405},
doi = {10.1080/03009742.2017.1337924},
issn = {1502-7732 (Electronic)
0300-9742 (Linking)},
year = {2017},
date = {2017-01-01},
journal = {Scand J Rheumatol},
pages = {1-8},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Englbrecht, M.; Alten, R.; Aringer, M.; Baerwald, C. G.; Burkhardt, H.; Eby, N.; Fliedner, G.; Gauger, B.; Henkemeier, U.; Hofmann, M. W.; Kleinert, S.; Kneitz, C.; Krueger, K.; Pohl, C.; Roske, A. E.; Schett, G.; Schmalzing, M.; Tausche, A. K.; Tony, H. Peter; Wendler, J.: Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge. In: Arthritis Care Res (Hoboken), Bd. 69, Nr. 1, S. 58-66, 2017, ISSN: 2151-4658 (Electronic)
2151-464X (Linking). @article{RN8198,
title = {Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge},
author = {M. Englbrecht and R. Alten and M. Aringer and C. G. Baerwald and H. Burkhardt and N. Eby and G. Fliedner and B. Gauger and U. Henkemeier and M. W. Hofmann and S. Kleinert and C. Kneitz and K. Krueger and C. Pohl and A. E. Roske and G. Schett and M. Schmalzing and A. K. Tausche and H. Peter Tony and J. Wendler},
url = {https://www.ncbi.nlm.nih.gov/pubmed/27482854 http://onlinelibrary.wiley.com/store/10.1002/acr.23002/asset/acr23002.pdf?v=1&t=j4e9fhol&s=713b86ce15fe37f619af80435413e786b0ac549f},
doi = {10.1002/acr.23002},
issn = {2151-4658 (Electronic)
2151-464X (Linking)},
year = {2017},
date = {2017-01-01},
journal = {Arthritis Care Res (Hoboken)},
volume = {69},
number = {1},
pages = {58-66},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Figueiredo, C. P.; Bang, H.; Cobra, J. F.; Englbrecht, M.; Hueber, A. J.; Haschka, J.; Manger, B.; Kleyer, A.; Reiser, M.; Finzel, S.; Tony, H. P.; Kleinert, S.; Wendler, J.; Schuch, F.; Ronneberger, M.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Lorenz, H. M.; Nuesslein, H.; Alten, R.; Henes, J.; Krueger, K.; Rech, J.; Schett, G.: Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. In: Ann Rheum Dis, Bd. 76, Nr. 2, S. 399-407, 2017, ISSN: 1468-2060 (Electronic)
0003-4967 (Linking). @article{RN8609,
title = {Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs},
author = {C. P. Figueiredo and H. Bang and J. F. Cobra and M. Englbrecht and A. J. Hueber and J. Haschka and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nuesslein and R. Alten and J. Henes and K. Krueger and J. Rech and G. Schett},
url = {https://www.ncbi.nlm.nih.gov/pubmed/27323772
http://ard.bmj.com/content/annrheumdis/76/2/399.full.pdf},
doi = {10.1136/annrheumdis-2016-209297},
issn = {1468-2060 (Electronic)
0003-4967 (Linking)},
year = {2017},
date = {2017-01-01},
journal = {Ann Rheum Dis},
volume = {76},
number = {2},
pages = {399-407},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Rosée, P. La; Krüger, K.: Rheumatische Krankheitserscheinungen bei hämatologischen Neoplasien. In: Zeitschrift für Rheumatologie, Bd. 76, Nr. 2, S. 38-45, 2017, ISSN: 1435-1250. @article{RN8878,
title = {Rheumatische Krankheitserscheinungen bei hämatologischen Neoplasien},
author = {S. Kleinert and P. La Rosée and K. Krüger},
url = {https://doi.org/10.1007/s00393-017-0338-9
https://link.springer.com/content/pdf/10.1007%2Fs00393-017-0338-9.pdf},
doi = {10.1007/s00393-017-0338-9},
issn = {1435-1250},
year = {2017},
date = {2017-01-01},
journal = {Zeitschrift für Rheumatologie},
volume = {76},
number = {2},
pages = {38-45},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Englbrecht, Matthias; Alten, Rieke; Aringer, Martin; Baerwald, Christoph G.; Burkhardt, Harald; Eby, Nancy; Fliedner, Gerhard; Gauger, Bettina; Henkemeier, Ulf; Hofmann, Michael W.; Kleinert, Stefan; Kneitz, Christian; Krueger, Klaus; Pohl, Christoph; Roske, Anne-Eve; Schett, Georg; Schmalzing, Marc; Tausche, Anne-Kathrin; Tony, Hans Peter; Wendler, Joerg: Validation of standardized questionnaires evaluating symptoms of depression in rheumatoid arthritis patients - approaches to screening for a frequent and yet underrated challenge. In: Arthritis Care & Research, S. n/a-n/a, 2016, ISSN: 2151-4658. @article{RN9108,
title = {Validation of standardized questionnaires evaluating symptoms of depression in rheumatoid arthritis patients - approaches to screening for a frequent and yet underrated challenge},
author = {Matthias Englbrecht and Rieke Alten and Martin Aringer and Christoph G. Baerwald and Harald Burkhardt and Nancy Eby and Gerhard Fliedner and Bettina Gauger and Ulf Henkemeier and Michael W. Hofmann and Stefan Kleinert and Christian Kneitz and Klaus Krueger and Christoph Pohl and Anne-Eve Roske and Georg Schett and Marc Schmalzing and Anne-Kathrin Tausche and Hans Peter Tony and Joerg Wendler},
url = {https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.23002},
doi = {10.1002/acr.23002},
issn = {2151-4658},
year = {2016},
date = {2016-01-01},
journal = {Arthritis Care & Research},
pages = {n/a-n/a},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Haschka, J.; Englbrecht, M.; Hueber, A. J.; Manger, B.; Kleyer, A.; Reiser, M.; Finzel, S.; Tony, H. P.; Kleinert, S.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Wendler, J.; Schuch, F.; Ronneberger, M.; Lorenz, H. M.; Nuesslein, H.; Alten, R.; Demary, W.; Henes, J.; Schett, G.; Rech, J.: Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. In: Ann Rheum Dis, Bd. 75, Nr. 1, S. 45-51, 2016, ISSN: 1468-2060 (Electronic)
0003-4967 (Linking). @article{RN7751,
title = {Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study},
author = {J. Haschka and M. Englbrecht and A. J. Hueber and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and J. Wendler and F. Schuch and M. Ronneberger and H. M. Lorenz and H. Nuesslein and R. Alten and W. Demary and J. Henes and G. Schett and J. Rech},
url = {http://www.ncbi.nlm.nih.gov/pubmed/25660991},
doi = {10.1136/annrheumdis-2014-206439},
issn = {1468-2060 (Electronic)
0003-4967 (Linking)},
year = {2016},
date = {2016-01-01},
journal = {Ann Rheum Dis},
volume = {75},
number = {1},
pages = {45-51},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Waldner, M.; Wendler, J.; Kunzmann, V.: [Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer]. In: Z Rheumatol, Bd. 75, Nr. 1, S. 41-6, 2016, ISSN: 1435-1250 (Electronic)
0340-1855 (Linking). @article{RN8064,
title = {[Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer]},
author = {S. Kleinert and M. Waldner and J. Wendler and V. Kunzmann},
url = {http://www.ncbi.nlm.nih.gov/pubmed/26786168 http://download.springer.com/static/pdf/163/art%253A10.1007%252Fs00393-015-0032-8.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00393-015-0032-8&token2=exp=1456567687~acl=%2Fstatic%2Fpdf%2F163%2Fart%25253A10.1007%25252Fs00393-015-0032-8.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00393-015-0032-8*~hmac=22a15e98f1b4a995584b830b445c6680f14e09356e23796ba3df76a7f0d4004b},
doi = {10.1007/s00393-015-0032-8},
issn = {1435-1250 (Electronic)
0340-1855 (Linking)},
year = {2016},
date = {2016-01-01},
journal = {Z Rheumatol},
volume = {75},
number = {1},
pages = {41-6},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Rech, J.; Hueber, A. J.; Finzel, S.; Englbrecht, M.; Haschka, J.; Manger, B.; Kleyer, A.; Reiser, M.; Cobra, J. F.; Figueiredo, C.; Tony, H. P.; Kleinert, S.; Wendler, J.; Schuch, F.; Ronneberger, M.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Lorenz, H. M.; Nuesslein, H.; Alten, R.; Henes, J.; Krueger, K.; Schett, G.: Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. In: Ann Rheum Dis, Bd. 75, Nr. 9, S. 1637-44, 2016, ISSN: 1468-2060 (Electronic)
0003-4967 (Linking). @article{RN8206,
title = {Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment},
author = {J. Rech and A. J. Hueber and S. Finzel and M. Englbrecht and J. Haschka and B. Manger and A. Kleyer and M. Reiser and J. F. Cobra and C. Figueiredo and H. P. Tony and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nuesslein and R. Alten and J. Henes and K. Krueger and G. Schett},
url = {https://www.ncbi.nlm.nih.gov/pubmed/26483255
http://ard.bmj.com/content/annrheumdis/75/9/1637.full.pdf},
doi = {10.1136/annrheumdis-2015-207900},
issn = {1468-2060 (Electronic)
0003-4967 (Linking)},
year = {2016},
date = {2016-01-01},
journal = {Ann Rheum Dis},
volume = {75},
number = {9},
pages = {1637-44},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Feuchtenberger, M.; Kleinert, S.; Scharbatke, E. C.; Gnann, H.; Behrens, F.; Wittig, B. M.; Greger, G.; Tony, H. P.: The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis. In: Clin Exp Rheumatol, Bd. 33, Nr. 3, S. 321-9, 2015, ISSN: 0392-856X (Print)
0392-856X (Linking). @article{RN7752,
title = {The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis},
author = {M. Feuchtenberger and S. Kleinert and E. C. Scharbatke and H. Gnann and F. Behrens and B. M. Wittig and G. Greger and H. P. Tony},
url = {http://www.ncbi.nlm.nih.gov/pubmed/25897681},
issn = {0392-856X (Print)
0392-856X (Linking)},
year = {2015},
date = {2015-01-01},
journal = {Clin Exp Rheumatol},
volume = {33},
number = {3},
pages = {321-9},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Haschka, J.; Englbrecht, M.; Hueber, A. J.; Manger, B.; Kleyer, A.; Reiser, M.; Finzel, S.; Tony, H. P.; Kleinert, S.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Wendler, J.; Schuch, F.; Ronneberger, M.; Lorenz, H. M.; Nuesslein, H.; Alten, R.; Demary, W.; Henes, J.; Schett, G.; Rech, J.: Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. In: Ann Rheum Dis, 2015, ISSN: 0003-4967. @article{RN9102,
title = {Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study},
author = {J. Haschka and M. Englbrecht and A. J. Hueber and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and J. Wendler and F. Schuch and M. Ronneberger and H. M. Lorenz and H. Nuesslein and R. Alten and W. Demary and J. Henes and G. Schett and J. Rech},
url = {https://ard.bmj.com/content/annrheumdis/75/1/45.full.pdf},
doi = {10.1136/annrheumdis-2014-206439},
issn = {0003-4967},
year = {2015},
date = {2015-01-01},
journal = {Ann Rheum Dis},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
